<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Fluvoxamine for the treatment of COVID‐19 - Nyirenda, JLZ - 2022 | Cochrane Library</title> <meta content="Fluvoxamine for the treatment of COVID‐19 - Nyirenda, JLZ - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015391/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Fluvoxamine for the treatment of COVID‐19 - Nyirenda, JLZ - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015391/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015391" name="dc.identifier" scheme="DOI"/> <meta content="Fluvoxamine for the treatment of COVID‐19" name="citation_title"/> <meta content="John LZ Nyirenda&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Mario Sofroniou&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Ingrid Toews" name="citation_author"/> <meta content="Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg" name="citation_author_institution"/> <meta content="Agata Mikolajewska" name="citation_author"/> <meta content="Cornelius Lehane" name="citation_author"/> <meta content="University Heart Center Freiburg, Bad Krozingen" name="citation_author_institution"/> <meta content="Ina Monsef" name="citation_author"/> <meta content="Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematology" name="citation_author_institution"/> <meta content="Aesha Abu-taha" name="citation_author"/> <meta content="Faculty of Medicine, Medical Center – University of Freiburg" name="citation_author_institution"/> <meta content="Andy Maun" name="citation_author"/> <meta content="Faculty of Medicine, Medical Center – University of Freiburg" name="citation_author_institution"/> <meta content="Miriam Stegemann" name="citation_author"/> <meta content="Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin" name="citation_author_institution"/> <meta content="Christine Schmucker" name="citation_author"/> <meta content="Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg" name="citation_author_institution"/> <meta content="schmucker@cochrane.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD015391" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/09/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015391/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015391/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015391/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Clinical Deterioration; *COVID-19 Drug Treatment; Fluvoxamine [pharmacology, therapeutic use]; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015391&amp;doi=10.1002/14651858.CD015391&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="VXKc2U6b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015391\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015391\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015391\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","pt","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015391",title:"Fluvoxamine for the treatment of COVID\\u201019",firstPublishedDate:"Sep 14, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015391&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015391';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015391/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015391/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015391%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015391/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015391/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015391/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015391/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015391" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015391/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015391" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015391/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015391/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6799 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015391" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-sec-0051"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015391/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/appendices#CD015391-sec-0093"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/supinfo/CD015391StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/supinfo/CD015391StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015391/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015391/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015391/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015391/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015391/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Fluvoxamine for the treatment of COVID‐19</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Shared first authorship"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0004">John LZ Nyirenda</a><sup>a</sup></li> <li class="author custom-tooltip" title="Shared first authorship"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0005">Mario Sofroniou</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0006">Ingrid Toews</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0007">Agata Mikolajewska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0008">Cornelius Lehane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0009">Ina Monsef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0010">Aesha Abu-taha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0011">Andy Maun</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0012">Miriam Stegemann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015391/information#CD015391-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Christine Schmucker</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015391/information/en#CD015391-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 September 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015391/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015391">https://doi.org/10.1002/14651858.CD015391</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015391-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015391-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015391-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015391-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015391-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015391-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015391-abs-0010">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015391-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015391-abs-0001" lang="en"> <section id="CD015391-sec-0001"> <h3 class="title" id="CD015391-sec-0001">Background</h3> <p>Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) that has been approved for the treatment of depression, obsessive–compulsive disorder, and a variety of anxiety disorders; it is available as an oral preparation. Fluvoxamine has not been approved for the treatment of infections, but has been used in the early treatment of people with mild to moderate COVID‐19. As there are only a few effective therapies for people with COVID‐19 in the community, a thorough understanding of the current evidence regarding the efficacy and safety of fluvoxamine as an anti‐inflammatory and possible anti‐viral treatment for COVID‐19, based on randomised controlled trials (RCTs), is needed. </p> </section> <section id="CD015391-sec-0002"> <h3 class="title" id="CD015391-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of fluvoxamine in addition to standard care, compared to standard care (alone or with placebo), or any other active pharmacological comparator with proven efficacy for the treatment of COVID‐19 outpatients and inpatients. </p> </section> <section id="CD015391-sec-0003"> <h3 class="title" id="CD015391-sec-0003">Search methods</h3> <p>We searched the Cochrane COVID‐19 Study Register (including Cochrane Central Register of Controlled Trials, MEDLINE, Embase, ClinicalTrials.gov, WHO ICTRP, medRxiv), Web of Science and WHO COVID‐19 Global literature on COVID‐19 to identify completed and ongoing studies up to 1 February 2022. </p> </section> <section id="CD015391-sec-0004"> <h3 class="title" id="CD015391-sec-0004">Selection criteria</h3> <p>We included RCTs that compared fluvoxamine in addition to standard care (also including no intervention), with standard care (alone or with placebo), or any other active pharmacological comparator with proven efficacy in clinical trials for the treatment of people with confirmed COVID‐19, irrespective of disease severity, in both inpatients and outpatients. Co‐interventions needed to be the same in both study arms. We excluded studies comparing fluvoxamine to other pharmacological interventions with unproven efficacy. </p> </section> <section id="CD015391-sec-0005"> <h3 class="title" id="CD015391-sec-0005">Data collection and analysis</h3> <p>We assessed risk of bias of primary outcomes using the Cochrane Risk of Bias 2 tool for RCTs. We used GRADE to rate the certainty of evidence to treat people with asymptomatic to severe COVID‐19 for the primary outcomes including mortality, clinical deterioration, clinical improvement, quality of life, serious adverse events, adverse events of any grade, and suicide or suicide attempt. </p> </section> <section id="CD015391-sec-0006"> <h3 class="title" id="CD015391-sec-0006">Main results</h3> <p>We identified two completed studies with a total of 1649 symptomatic participants. One study was conducted in the USA (study with 152 participants, 80 and 72 participants per study arm) and the other study in Brazil (study with 1497 high‐risk participants for progression to severe disease, 741 and 756 participants per study arm) among outpatients with mild COVID‐19. Both studies were double‐blind, placebo‐controlled trials in which participants were prescribed 100 mg fluvoxamine two or three times daily for a maximum of 15 days. </p> <p>We identified five ongoing studies and two studies awaiting classification (due to translation issues, and due to missing published data). We found no published studies comparing fluvoxamine to other pharmacological interventions of proven efficacy. </p> <p>We assessed both included studies to have an overall high risk of bias.</p> <p><b>Fluvoxamine for the treatment of COVID‐19 in inpatients</b> </p> <p>We did not identify any completed studies of inpatients.</p> <p><b>Fluvoxamine for the treatment of COVID‐19 in outpatients</b> </p> <p>Fluvoxamine in addition to standard care may slightly reduce all‐cause mortality at day 28 (RR 0.69, 95% CI 0.38 to 1.27; risk difference (RD) 9 per 1000; 2 studies, 1649 participants; low‐certainty evidence), and may reduce clinical deterioration defined as all‐cause hospital admission or death before hospital admission (RR 0.55, 95% CI 0.16 to 1.89; RD 57 per 1000; 2 studies, 1649 participants; low‐certainty evidence). We are very uncertain regarding the effect of fluvoxamine on serious adverse events (RR 0.56, 95% CI 0.15 to 2.03; RD 54 per 1000; 2 studies, 1649 participants; very low‐certainty evidence) or adverse events of any grade (RR 1.06, 95% CI 0.82 to 1.37; RD 7 per 1000; 2 studies, 1649 participants; very low‐certainty evidence). </p> <p>Neither of the studies reported on symptom resolution (clinical improvement), quality of life or suicide/suicide attempt. </p> </section> <section id="CD015391-sec-0007"> <h3 class="title" id="CD015391-sec-0007">Authors' conclusions</h3> <p>Based on a low‐certainty evidence, fluvoxamine may slightly reduce all‐cause mortality at day 28, and may reduce the risk of admission to hospital or death in outpatients with mild COVID‐19. However, we are very uncertain regarding the effect of fluvoxamine on serious adverse events, or any adverse events. </p> <p>In accordance with the living approach of this review, we will continually update our search and include eligible trials as they arise, to complete any gaps in the evidence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015391-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015391-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015391-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015391-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015391-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015391-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD015391-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015391-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015391-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD015391-abs-0018">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015391-abs-0011">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD015391-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015391-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015391-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015391-abs-0002" lang="en"> <h3>Fluvoxamine for treating COVID‐19</h3> <p><b>Review question</b> </p> <p>Is fluvoxamine an effective treatment for people with COVID‐19 and does it cause any unwanted effects? </p> <p><b>Key messages</b> </p> <p>It is unclear whether fluvoxamine is an effective treatment for COVID‐19 in people with mild to moderate COVID‐19. This is because there is currently not enough research available to make a definite decision. <br/>We found five ongoing studies that are currently investigating fluvoxamine as a possible treatment for COVID‐19, and two studies for which we need more information. We will update this review if their results change our conclusions. </p> <p><b>What is fluvoxamine?</b> </p> <p>Fluvoxamine is a type of medication known as a selective serotonin reuptake inhibitor (SSRI), available in tablet form. Recent research has found that fluvoxamine may have an effect on COVID‐19. When the immune system fights the virus, the lungs and airways can become inflamed, causing breathing difficulties. Fluvoxamine could help reduce this inflammation, potentially reducing the risk of developing severe COVID‐19 and its associated lung symptoms through its possible anti‐inflammatory and anti‐viral effects. We know that most people do not experience any serious side effects with fluvoxamine when it is taken as an antidepressant. Some people can, however, experience the following common side effects, especially when starting the medication: nausea, anxiety or restlessness, insomnia, or diarrhoea, and in rare cases, suicidal ideation. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know if fluvoxamine reduces death, severity of disease, and length of infection in people with COVID‐19, if it has an effect on quality of life, or causes any unwanted effects. We included studies that compared fluvoxamine to placebo (dummy treatment), no treatment, usual care, or any other treatment for COVID‐19 that is known to work to some extent, such as remdesivir or dexamethasone. We excluded treatments that we know do not work for COVID‐19, such as hydroxychloroquine, or have an unknown effect on the disease. </p> <p>We evaluated the effects of fluvoxamine in adults with COVID‐19 on:</p> <p>• people dying;</p> <p>• whether people needed to be treated in a hospital;</p> <p>• whether people's COVID‐19 symptoms got better or worse;</p> <p>• unwanted effects;</p> <p>• quality of life;</p> <p>• and whether there is a risk of suicide or suicide attempt when taking this medication.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated fluvoxamine as a treatment for adults with COVID‐19 in hospital or as outpatients. We compared and summarised the results of the studies and rated our confidence in the evidence, based on common criteria such as study methods and study sizes. </p> <p><b>What did we find?</b> </p> <p>We found two studies that investigated fluvoxamine as an early treatment for mild COVID‐19 in 1649 self‐isolated people at home (outpatients). All studies compared fluvoxamine to placebo together with standard care. The studies used different durations of treatment (10 or 15 days). </p> <p>We found five ongoing studies and two studies that are awaiting classification. We did not find any studies that investigated the effect of fluvoxamine on people in hospital with COVID‐19. </p> <p><b>Main results</b> </p> <p>• Compared to placebo, fluvoxamine may slightly reduce the number of people who die in the 28 days after starting treatment (2 studies, 1649 people). </p> <p>• Compared to placebo, fluvoxamine may reduce number of people who are admitted to a hospital or who die before hospital admission (2 studies, 1649 people). </p> <p>•The number of unwanted (serious) events did not clearly differ between fluvoxamine and placebo treatment (2 studies, 1649 people). </p> <p>•Neither of the studies reported on quality of life, the time needed until all initial symptoms resolved, or suicide attempts. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We cannot be confident in the current evidence for fluvoxamine in treating people with COVID‐19, mainly due to the lack of studies that are currently available and some flaws in study design. We will continue to search for new studies to complete the current evidence gap. </p> <p>It would also be important to find out the effects of a medication such as fluvoxamine on long‐Covid. We are currently waiting for research on this to become available in the near future. </p> <p>Unfortunately, the studies available did not focus on children and young adults, women who are planning or trying to conceive, women who are pregnant or breastfeeding, older adults, or those people who have a weakened immune system (immunocompromised people). Likewise, no information was available on whether women or men were more likely to benefit from fluvoxamine. </p> <p><b>Search date</b> </p> <p>The evidence is current to February 2022.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015391-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015391-sec-0088"></div> <h3 class="title" id="CD015391-sec-0089">Implications for practice</h3> <section id="CD015391-sec-0089"> <p>Based on the current evidence, the use of fluvoxamine plus standard care in comparison to standard care plus placebo in outpatients with mild COVID‐19 may reduce slightly all cause mortality (at day 28) and may reduce admission to hospital or death. However, we are very uncertain regarding the effect on serious adverse events. These findings are restricted to unvaccinated symptomatic outpatients and virus variants of concern that were present at the time that the trials were conducted. There were no numerical data currently available for other prioritised outcomes, including symptom resolution, quality of life, and suicide. No completed studies were identified that focused on inpatients, hence no statements could be made on this aspect of fluvoxamine use. </p> </section> <h3 class="title" id="CD015391-sec-0090">Implications for research</h3> <section id="CD015391-sec-0090"> <p>Effective pharmacological therapies to treat COVID‐19 in the outpatient setting are important to reduce the risk of progression to severe disease in people with COVID‐19, and reduce the need for hospital admission. Trials considering both prioritised outcomes, such as quality of life, and current vaccination status, as well as older populations, women who are pregnant or breastfeeding, or people who have a weakened immune system are needed to further investigate the role of fluvoxamine in the treatment of COVID‐19. Furthermore, it would be important to establish the efficacy and safety of fluvoxamine as compared to other active pharmacotherapies targeting novel COVID‐19 variants, and whether closely related selective serotonin reuptake inhibitors could be used interchangeably. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015391-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015391-sec-0008"></div> <div class="table" id="CD015391-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> symptomatic people with COVID‐19 </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> fluvoxamine plus standard care </p> <p><b>Comparison:</b> placebo plus standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects (95% CI)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty in the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo plus standard care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with fluvoxamine plus standard care</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>(at day 28)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> <p>(95% CI 11 to 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> <p>(95% CI 2 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.69</p> <p>(0.38 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluvoxamine may slightly reduce all‐cause mortality at day 28.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>All‐cause admission to hospital or death (before hospital admission)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> <p>(95% CI 105 to 150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> <p>(95% CI 76 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.55</p> <p>(0.16 to 1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649</p> <p>(2 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluvoxamine may reduce admission to hospital or death (before hospital admission).</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Symptom resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>All initial symptoms resolved</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Time to symptom resolution</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Numerical data not derivable, outcome was illustrated in a figure (graph) indicating an overlap of confidence intervals (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p>(at longest follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during study period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000 (95% CI 18 to 248)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> <p>(95% CI 41 to 221)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.56</p> <p>(0.15 to 2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effects of fluvoxamine on serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Any adverse events</b> </p> <p>(during study period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> <p>(95% CI 97 to 162)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> <p>(95% CI 104 to 169)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06</p> <p>(0.82 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effects of fluvoxamine on any adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Suicide or suicide attempt</b> </p> <p>(at longest follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The risk in the intervention group and its 95% CI is based on the assumed risk in the comparison group and the relative effect of the intervention and its 95% CI. </p> <p>CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Risk difference 9 per 1000 (19 fewer to 8 more), small important effect (since mortality is the most critical outcomes for patients and clinicians). Downgraded by 2 levels for very serious imprecision since CI suggests both potential benefit and no effect/potential harm, and number of events is small.<br/><sup>b</sup>Risk difference 57 per 1000 (106 fewer to 112 more), moderate effect. Downgraded by 2 levels for very serious imprecision since CI suggests both potential benefit and no effect/potential harm, and number of events is small.<br/><sup>c</sup>Risk difference 54 per 1000 (50 fewer to 4 more), moderate effect. Downgraded by 1 level for serious risk of bias and by 2 levels for very serious imprecision since CI suggests both potential benefit and potential harm.<br/><sup>d</sup>Risk difference 7 per 1000 (21 fewer to 44 more), small unimportant effect. Downgraded by 1 level for serious risk of bias and by 2 levels for very serious imprecision since CI suggests both potential benefit and potential harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015391-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015391-sec-0009"></div> <p>This work constitutes part of a series of Cochrane Reviews investigating the use of potential pharmacotherapies for coronavirus disease 2019 (COVID‐19) in both inpatients and outpatients. This particular review evaluates the efficacy and safety of fluvoxamine, specifically evaluating its possible use in ambulatory‐managed patients, from here on referred to as outpatients, but also considers inpatients. Reviews in this series carry a degree of overlap with the background and methodology sections of other published reviews from the German research project 'CEOsys' (COVID‐19 Evidence Ecosystem) on antibiotics (<a href="./references#CD015391-bbs2-0067" title="PoppM , StegemannM , RiemerM , Metzendorf M-I, RomeroCS , MikolajewskaA , et al. Antibiotics for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD015025. [DOI: 10.1002/14651858.CD015025]">Popp 2021a</a>), monoclonal antibodies (<a href="./references#CD015391-bbs2-0049" title="KreuzbergerN , HirschC , ChaiKL , TomlinsonE , KhosraviZ , PoppM , et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825.pub2]">Kreuzberger 2021</a>), convalescent plasma (<a href="./references#CD015391-bbs2-0065" title="PiechottaV , IannizziC , ChaiKL , ValkSJ , KimberC , DorandoE , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2022, Issue 2. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4]">Piechotta 2022</a>), ivermectin (<a href="./references#CD015391-bbs2-0067" title="PoppM , StegemannM , RiemerM , Metzendorf M-I, RomeroCS , MikolajewskaA , et al. Antibiotics for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD015025. [DOI: 10.1002/14651858.CD015025]">Popp 2021a</a>), vitamin D supplementation (<a href="./references#CD015391-bbs2-0079" title="StroehleinJK , WallqvistJ , IannizziC , MikolajewskaA , MetzendorfMI , BenstoemC , et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD015043. [DOI: 10.1002/14651858.CD015043]">Stroehlein 2021</a>), systemic corticosteroids (<a href="./references#CD015391-bbs2-0085" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014963. [DOI: 10.1002/14651858.CD014963]">Wagner 2021</a>), colchicine (<a href="./references#CD015391-bbs2-0054" title="MikolajewskaA , FischerAL , PiechottaV , MuellerA , MetzendorfMI , et al. Colchicine for the treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD015045. [DOI: 10.1002/14651858.CD015045]">Mikolajewska 2021</a>) and remdesivir (<a href="./references#CD015391-bbs2-0024" title="AnsemsK , GrundeisF , DahmsK , MikolajewskaA , ThiemeV , PiechottaV , et al. Remdesivir for the treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014962. [DOI: 10.1002/14651858.CD014962]">Ansems 2021</a>). </p> <section id="CD015391-sec-0010"> <h3 class="title" id="CD015391-sec-0010">Description of the condition</h3> <p>COVID‐19 is a rapidly spreading infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) (<a href="./references#CD015391-bbs2-0090" title="World Health Organization. Report of the WHO-China JointMission on coronavirus disease 2019 (COVID-19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-oncovid-19-final-report (accessed 6 December 2021).">WHO 2020a</a>). COVID‐19 is unprecedented in comparison to previous coronavirus outbreaks such as SARS and Middle East Respiratory Syndrome (MERS), which caused 813 and 858 deaths, respectively (<a href="./references#CD015391-bbs2-0088" title="World Health Organization. Cumulative number of reported probable cases of SARS; 2003. www.who.int/csr/sars/country/2003_07_11/en (accessed 16 December 2021).">WHO 2003</a>; <a href="./references#CD015391-bbs2-0089" title="World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV): 2019. www.who.int/emergencies/mers-cov/en (accessed 6 December 2021).">WHO 2019a</a>). Despite international efforts to contain its spread, as of February 2022, COVID‐19 had resulted in more than 420 million confirmed cases and over 5.9 million deaths worldwide (<a href="./references#CD015391-bbs2-0097" title="World Health Organization. WHO Coronavirus (COVID-19) Dashboard. covid19.who.int/ (accessed 25 February 2022).">WHO2022a</a>). The emergence of novel SARS‐CoV‐2 variants is also of great concern, with the potential for augmented transmission of the disease, a shortened incubation period and a negative impact on established and proven disease control methods (<a href="./references#CD015391-bbs2-0037" title="GrubaughND , HanageWP , RasmussenAL . Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell2020;182(4):794-5. [DOI: 10.1016/j.cell.2020.06.040]">Grubaugh 2020</a>; <a href="./references#CD015391-bbs2-0094" title="World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int (accessed 25 February 2022).">WHO 2021a</a>). </p> <p>Vaccination has been shown to be highly effective in reducing severe illness and death from COVID‐19. More than 10.4 billion doses of vaccines had been administered globally as of February 2022, with additional vaccines in continuous development (<a href="./references#CD015391-bbs2-0097" title="World Health Organization. WHO Coronavirus (COVID-19) Dashboard. covid19.who.int/ (accessed 25 February 2022).">WHO2022a</a>). The majority of vaccines have been administered in high‐income countries, leaving populations including health care workers and older people in other countries vulnerable. </p> <p>The mean incubation period is estimated at five to six days, with 97.5% of cases developing symptoms within 11.5 days of exposure (<a href="./references#CD015391-bbs2-0050" title="LauerSA , GrantzKH , BiQ , JonesFK , ZhengQ , MeredithHR , et al. The incubation period of coronavirus disease 2019(COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine2020;172(9):577–82. [DOI: 10.7326/M20-0504]">Lauer 2020</a>). Sore throat, cough, fever, headache, fatigue, myalgia (muscle pain) and arthralgia (joint pain) are the most commonly reported symptoms (<a href="./references#CD015391-bbs2-0080" title="StruyfT , DeeksJJ , DinnesJ , TakwoingiY , DavenportC , LeeflangMM , et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013665. [DOI: 10.1002/14651858.CD013665]">Struyf 2020</a>). Other symptoms may include dyspnoea, rigors, nausea and vomiting, diarrhoea, and nasal congestion (<a href="./references#CD015391-bbs2-0090" title="World Health Organization. Report of the WHO-China JointMission on coronavirus disease 2019 (COVID-19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-oncovid-19-final-report (accessed 6 December 2021).">WHO 2020a</a>). The majority of infected individuals develop mild symptoms not requiring hospitalisation, or remain completely asymptomatic (80% to 90%) depending on the timing of the investigation, the cohort investigated, and the virus variant (<a href="./references#CD015391-bbs2-0027" title="ChenT , WuD , ChenH , YanW , YangD , ChenG , et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020 March 26 [Epub ahead of print]:1-12. [DOI: 10.1136/bmj.m1091]">Chen 2020</a>; <a href="./references#CD015391-bbs2-0029" title="DanzaP , KooTH , HaddixM , FisherR , TraubE , YongK , et al. SARS-CoV-2 infection and hospitalization among adults aged≥ 18 Years, by vaccination status, before and during SARS-CoV-2 B. 1.1. 529 (omicron) variant predominance—Los Angeles County, California, November 7, 2021 to January 8, 2022. Morbidity and Mortality Weekly Report2022;71(5):177. [DOI: 10.15585/mmwr.mm7105e1]">Danza 2022</a>; <a href="./references#CD015391-bbs2-0035" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7,B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Europe's Journal on Infectious Disease Surveillance, Epidemiology, Prevention and Control2021;26(16):pii=2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015391-bbs2-0064" title="PanA , LiuL , WangC , GuoH , HaoX , WangQ , et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. Journal of the American Medical Association2020;323(19):1915-23. [DOI: 10.1001/jama.2020.6130]">Pan 2020</a>; <a href="./references#CD015391-bbs2-0099" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). The reported frequency of asymptomatic cases also varies greatly and ranges from 6% to 96% (<a href="./references#CD015391-bbs2-0026" title="Buitrago-GarciaD , Egli-GanyD , CounotteMJ , HossmannS , ImeriH , Ipekci AzizM , et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2infections: a living systematic review and meta-analysis. PloS Medicine2020;17(9):e1003346. [DOI: 10.1371/ journal.pmed.1003346]">Buitrago‐Garcia 2020</a>; <a href="./references#CD015391-bbs2-0035" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7,B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Europe's Journal on Infectious Disease Surveillance, Epidemiology, Prevention and Control2021;26(16):pii=2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015391-bbs2-0062" title="OranDP , TopolEJ . Prevalence of asymptomatic SARS-CoV-2infection: a narrative review. Annals of Internal Medicine2020;173(5):362-7. [DOI: 10.7326/M20-3012]">Oran 2020</a>). </p> <p>In the first two years of the pandemic (2020 to 2021), there were estimates that approximately 11% to 20% of infected individuals went on to develop severe disease, with 1% to 5% developing critical illness with respiratory failure, septic shock or multi‐organ dysfunction syndrome requiring intensive care unit (ICU) treatment (<a href="./references#CD015391-bbs2-0035" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7,B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Europe's Journal on Infectious Disease Surveillance, Epidemiology, Prevention and Control2021;26(16):pii=2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015391-bbs2-0043" title="HuangC , WangY , LiX , RenL , ZhaoJ , HuY , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395(10223):497-506. [DOI: 10.1016/S0140-6736(20)30183-5]">Huang 2020</a>; <a href="./references#CD015391-bbs2-0099" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). Furthermore, COVID‐19 case fatality rates varied widely between countries and reporting periods, from 0% to over 25% (<a href="./references#CD015391-bbs2-0046" title="Johns Hopkins University &amp; Medicine Coronavirus Resource Center. Mortality analyses: How does mortality differ across countries?coronavirus.jhu.edu/data/mortality (accessed 10 February 2022).">Johns Hopkins University of Medicine 2022</a>; <a href="./references#CD015391-bbs2-0098" title="WilliamsonE , WalkerAJ , BhaskaranKJ , BaconS , BatesC , MortonCE , et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature2020;584(7821):430-6. [DOI: 10.1038/s41586-020-2521-4]">Williamson 2020</a>). These numbers may have been misleading, as they depended on testing frequency, delays in reporting dates and incomplete capture of case data at the time (<a href="./references#CD015391-bbs2-0046" title="Johns Hopkins University &amp; Medicine Coronavirus Resource Center. Mortality analyses: How does mortality differ across countries?coronavirus.jhu.edu/data/mortality (accessed 10 February 2022).">Johns Hopkins University of Medicine 2022</a>; <a href="./references#CD015391-bbs2-0098" title="WilliamsonE , WalkerAJ , BhaskaranKJ , BaconS , BatesC , MortonCE , et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature2020;584(7821):430-6. [DOI: 10.1038/s41586-020-2521-4]">Williamson 2020</a>). Case definitions have been adjusted and modified during the course of the pandemic (<a href="./references#CD015391-bbs2-0091" title="World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020 (accessed 6 December 2021).">WHO 2020b</a>), whilst contemporary considerations such as the levels of immunity in the population and type of viral strains present at the time of data collection should also be taken into account (<a href="./references#CD015391-bbs2-0096" title="World Health Organization. Tracking SARS-CoV-2 variants. www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed 18 February 2022).">WHO 2022</a>). </p> </section> <section id="CD015391-sec-0011"> <h3 class="title" id="CD015391-sec-0011">Description of the intervention</h3> <p>Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) and a σ‐1 receptor (S1R) agonist that has been approved for the treatment of depression, obsessive–compulsive disorder, and a variety of anxiety disorders. Available as an oral preparation, it is widely prescribed in the primary care setting worldwide for major depressive and obsessive‐compulsive disorders; in treating anxiety disorders such as panic disorder, social anxiety disorder, and post‐traumatic stress (<a href="./references#CD015391-bbs2-0033" title="FiggittDP , McClellanKJ . Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. SpringerLink2000;60(4):925-54. [PMID: 11085201]">Figgit 2000</a>); as well as for menopausal symptoms and functional gut disorders (off‐label use). When fluvoxamine is used to treat psychiatric conditions, the most common adverse effect is nausea (particularly at the beginning of the treatment), but adverse effects can include other gastrointestinal effects (e.g. diarrhoea, indigestion), neurological effects (e.g. asthaenia, insomnia, somnolence, anxiety, headache), and suicidal ideation. There has been much discussion over the years about increased suicide rates in people taking serotonin reuptake inhibitors. Increased suicide rates are particularly evident in younger people (<a href="./references#CD015391-bbs2-0034" title="Friedman RA . Antidepressants' black-box warning — 10 years later. New England Journal of Medicine2014;371(18):1666-8. [DOI: 10.1056/nejmp1408480]">Friedman 2014</a>). </p> <p>Fluvoxamine can enhance the serotonergic effects of other SSRIs or monoamine oxidase inhibitors (MAOIs), resulting in serotonin syndrome; therefore, it should not be used within two weeks of administration of other SSRIs or MAOIs. Fluvoxamine may enhance the effects of antiplatelets and anticoagulants. Hence, people receiving these drugs should be closely monitored (<a href="./references#CD015391-bbs2-0048" title="KamPCA , ChangGWM . Selective serotonin reuptake inhibitors Pharmacology and clinical implications in anaesthesia and critical care medicine. Anaesthesia1997;52(10):982-8. [DOI: 10.1111/j.1365-2044.1997.162-az0176.x]">Kam 1997</a>). </p> </section> <section id="CD015391-sec-0012"> <h3 class="title" id="CD015391-sec-0012">How the intervention might work</h3> <p>There are many important mechanisms of action of fluvoxamine and other SSRIs that could play a role in COVID‐19 treatment. These effects include: reduction in platelet aggregation, decreased mast cell degranulation, interference with endolysosomal viral trafficking, regulation of inositol‐requiring enzyme 1α‐driven inflammation and increased melatonin levels, collectively having a direct antiviral effect, as well as regulating coagulopathy or mitigating the cytokine storm, which are known hallmarks of severe COVID‐19 (<a href="./references#CD015391-bbs2-0081" title="SukhatmeVP , ReiersenAM , VayttadenSJ , SukhatmeVV . Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Frontiers in Pharmacology2021;12:652688. [DOI: 10.3389/fphar.2021.652688]">Sukhatme 2021</a>). </p> <p>Anti‐inflammatory effects of certain pharmacological interventions are thought to be effective during phases of COVID‐19 with high inflammatory activity. S1R is an endoplasmic reticulum (ER) chaperone membrane protein involved in many cellular functions, including regulation of ER stress response–unfolded protein response and regulation of cytokine production in response to inflammatory triggers. In a preclinical model of septic shock, fluvoxamine was found to bind to S1R on immune cells, resulting in a reduced inflammatory response with inhibited cytokine production (<a href="./references#CD015391-bbs2-0072" title="RosenDA , SekiSM , Fernández-CastañedaA , BeiterRM , EcclesJD , WoodfolkJA , et al. Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science Translational Medicine2019;11(478):5266. [DOI: 10.1126/scitranslmed.aau5266]">Rosen 2019</a>). In the presence of fluvoxamine, S1R might prevent the ER stress sensor inositol‐requiring enzyme 1α from splicing and activating the mRNA of X‐box protein 1, a key regulator of cytokine production including interleukins IL‐6, IL‐8, IL‐1β, and IL‐12. </p> <p>The anti‐inflammatory effects of fluvoxamine through activation of S1R observed in preclinical studies suggest fluvoxamine could be evaluated as a treatment option for COVID‐19 in clinical settings (<a href="./references#CD015391-bbs2-0069" title="RafieeL , HajhashemiV , JavanmardSH . Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iranian Journal of Basic Medical Sciences2016;19(9):977-84. [PMID: PMC5080428]">Rafiee 2016</a>). The anti‐inflammatory effects of fluvoxamine were also shown by a significantly decreased expression of some inflammatory genes, such as intracellular adhesion molecule (ICAM1), vascular cell adhesion molecule (VCAM<sub>1</sub>), cyclooxygenase 2 (COX<sub>2</sub>), and inducible nitric oxide synthase (iNOS) in human endothelial cells and macrophages (<a href="./references#CD015391-bbs2-0084" title="vanHartenJ . Overview of the pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics1995;29(1):1-9. [DOI: 10.2165/00003088-199500291-00003]">van Harten 1995</a>). </p> <p>In a murine sepsis model, fluvoxamine was found to bind to the S1R on immune cells, resulting in reduced production of inflammatory cytokines (<a href="./references#CD015391-bbs2-0072" title="RosenDA , SekiSM , Fernández-CastañedaA , BeiterRM , EcclesJD , WoodfolkJA , et al. Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Science Translational Medicine2019;11(478):5266. [DOI: 10.1126/scitranslmed.aau5266]">Rosen 2019</a>). Furthermore, in‐vitro studies of human endothelial cells and macrophages showed that fluvoxamine reduced the expression of inflammatory genes (<a href="./references#CD015391-bbs2-0081" title="SukhatmeVP , ReiersenAM , VayttadenSJ , SukhatmeVV . Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Frontiers in Pharmacology2021;12:652688. [DOI: 10.3389/fphar.2021.652688]">Sukhatme 2021</a>). Ongoing studies are currently looking to establish whether the anti‐inflammatory effects of fluvoxamine observed in non‐clinical studies are relevant to the clinical setting of COVID‐19 (<a href="./references#CD015391-bbs2-0082" title="TakenakaY , TanakaR , KitabatakeK , KuramochiK , AokiS , TsukimotoM . Profiling differential effects of 5 selective serotonin reuptake inhibitors on TLRs-dependent and -independent IL-6 production in immune cells identifies fluoxetine as preferred anti-inflammatory drug candidate. Frontiers in Pharmacology2022;13:874375. [DOI: 10.3389/fphar.2022.874375]">Takenaka 2022</a>). </p> </section> <section id="CD015391-sec-0013"> <h3 class="title" id="CD015391-sec-0013">Why it is important to do this review</h3> <p>The COVID‐19 pandemic places healthcare systems under tremendous pressure to provide adequate care. The emergence of variants of concern (<a href="./references#CD015391-bbs2-0095" title="World Health Organization. SARS-CoV-2 Variants. www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/ (accessed 6 December 2021).">WHO 2021b</a>; <a href="./references#CD015391-bbs2-0096" title="World Health Organization. Tracking SARS-CoV-2 variants. www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed 18 February 2022).">WHO 2022</a>), with the potential for increased transmissibility and altered disease characteristics, combined with the ongoing scarcity of effective and established drug treatments, in addition to low global vaccination coverage (<a href="./references#CD015391-bbs2-0092" title="World Health Organization. DraR landscape of COVID-19 candidate vaccines. www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines (accessed 6 December 2021).">WHO 2020c</a>), highlights the obvious and urgent need for effective and safe pharmacotherapies. The repurposing of existing medications that are also widely available, inexpensive, and with well‐understood safety profiles, such as fluvoxamine, is of great importance. Evidence‐based reviews are therefore needed to guide clinical decision‐making for people with COVID‐19. </p> <p>Current treatment consists of supportive care with oxygen therapy in cases with moderate disease, and with respiratory support, such as mechanical ventilation, and extracorporeal membrane oxygenation in cases of severe disease (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0114" target="_blank">CDC 2020</a>; <a href="./references#CD015391-bbs2-0091" title="World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020 (accessed 6 December 2021).">WHO 2020b</a>). Overall, data from randomised controlled trials (RCTs) do not demonstrate a clear, major clinical benefit with most of the drugs evaluated thus far. Data from RCTs at this stage support the role of corticosteroids for severe COVID‐19 and clinical guidelines recommend their use (<a href="./references#CD015391-bbs2-0022" title="AgarwalA , RochwergB , LamontagneF , SiemieniukRA , AgoritsasT , AskieL , et al. A living WHO guideline on drugs for Covid-19. BMJ2020;m3379:1-14. [DOI: 10.1136/bmj.m3379]">Agarwal 2020</a>; <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0147" target="_blank">National COVID‐19 Clinical Evidence Taskforce 2021</a>). Further, tocilizumab and janus kinase inhibitor baricitinib are recommended for certain patient groups, while other drugs, such as hydroxychloroquine, azithromycin and ivermectin, are not recommended for the treatment of COVID‐19 (<a href="./references#CD015391-bbs2-0022" title="AgarwalA , RochwergB , LamontagneF , SiemieniukRA , AgoritsasT , AskieL , et al. A living WHO guideline on drugs for Covid-19. BMJ2020;m3379:1-14. [DOI: 10.1136/bmj.m3379]">Agarwal 2020</a>; <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0147" target="_blank">National COVID‐19 Clinical Evidence Taskforce 2021</a>). </p> <p>Effective therapy regimens are particularly necessary for the early viral phase of the disease in order to prevent a severe course of COVID‐19. Evidence is emerging about the efficacy of anti‐COVID‐19 specific neutralising monoclonal antibodies as early treatments for COVID‐19 (<a href="./references#CD015391-bbs2-0049" title="KreuzbergerN , HirschC , ChaiKL , TomlinsonE , KhosraviZ , PoppM , et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825.pub2]">Kreuzberger 2021</a>). If used in the early phase of the disease (up to day five to seven after the onset of symptoms), the neutralising monoclonal antibodies significantly reduce the risk of a severe course of the disease (<a href="./references#CD015391-bbs2-0038" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , FalciDR , et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. New England Journal of Medicine2021;385(21):1941-50. [DOI: 10.1056/NEJMoa2107934]">Gupta 2021</a>; <a href="./references#CD015391-bbs2-0086" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. New England Journal of Medicine2021;385(23):1-12. [DOI: 10.1056/NEJMoa2108163]">Weinreich 2021</a>). However, a parenteral form of administration and currently limited availability represent an important challenge that makes widespread use in the non‐hospitalised setting difficult. Furthermore, the effectiveness of many of the neutralising monoclonal antibodies against the new virus variants may be reduced (<a href="./references#CD015391-bbs2-0042" title="HoffmannM , KrügerN , SchulzS , CossmannA , RochaC , KempfA , et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell2021;185(3):447-56. [DOI: 10.1016/j.cell.2021.12.032]">Hoffmann 2021</a>; <a href="./references#CD015391-bbs2-0066" title="PlanasD , SaundersN , MaesP , Guivel-BenhassineF , PlanchaisC , BuchrieserJ , et al. Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization. Nature;602(7898):671-5. [DOI: 10.1101/2021.12.14.472630]">Planas 2022</a>). Other antiviral drugs are promising, such as the ribonucleoside analogue molnupiravir or the protease inhibitor nirmatrelvir in combination with ritonavir, but are still under investigation and not yet widely available (<a href="./references#CD015391-bbs2-0045" title="Jayk BernalA , Gomes da SilvaMM , MusungaieDB , KovalchukE , GonzalezA , Delos ReyesV , et al MOVe-OUT Study Group. Molnupiravir for oral treatment of COVID19 in nonhospitalized patients. New England Journal of Medicine2021:1-12. [DOI: 10.1056/NEJMoa2116044]">Jayk Bernal 2021</a>). </p> <p>Systematic reviews for interventions to treat COVID‐19 have already been undertaken, including treatment with fluvoxamine (<a href="./references#CD015391-bbs2-0047" title="KacimiSE , GrecaE , HairecheMA , ElHawarySA , SettiMO , CaruanaR , et al. The place of fluvoxamine in the treatment of non-critically ill patients with COVID-19: a living systematic review and meta-analysis. medRxiv2021. [DOI: 10.1101/2021.12.19.21268044]">Kacimi 2021</a>; <a href="./references#CD015391-bbs2-0051" title="LeeTC , VigodS , Bortolussi-CourvalE , HanulaR , BoulwareDR , LenzeEJ , et al. Fluvoxamine for outpatient COVID-19 to prevent hospitalization: a systematic review and meta-analysis. medRxiv. [DOI: 10.1101/2021.12.17.21268008]">Lee 2021</a>; <a href="./references#CD015391-bbs2-0055" title="MurchuOE , SpillaneS , ByrneP , O’NeillM , HarringtonP , RyanM . Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19: a systematic review. Annals of Pharmacotherapy2022;56(3):309-18. [DOI: 10.1177/10600280211028242]">Murchu 2022</a>; <a href="./references#CD015391-bbs2-0087" title="WenW , ChenC , TangJ , WangC , ZhouM , ChengY , et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Annals of Medicine2022;54(1):516-23. [DOI: 10.1080/07853890.2022.2034936]">Wen 2022</a>)<a href="https://link.springer.com/article/10.1007/s42398-021-00194-6)." target="_blank">.</a> However, they did not fulfil all the methodological standards for evidence synthesis. For example, they did not apply the GRADE approach for rating the certainty of the evidence or assess the risk of bias (<a href="./references#CD015391-bbs2-0047" title="KacimiSE , GrecaE , HairecheMA , ElHawarySA , SettiMO , CaruanaR , et al. The place of fluvoxamine in the treatment of non-critically ill patients with COVID-19: a living systematic review and meta-analysis. medRxiv2021. [DOI: 10.1101/2021.12.19.21268044]">Kacimi 2021</a>; <a href="./references#CD015391-bbs2-0087" title="WenW , ChenC , TangJ , WangC , ZhouM , ChengY , et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Annals of Medicine2022;54(1):516-23. [DOI: 10.1080/07853890.2022.2034936]">Wen 2022</a>). Furthermore, <a href="./references#CD015391-bbs2-0055" title="MurchuOE , SpillaneS , ByrneP , O’NeillM , HarringtonP , RyanM . Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19: a systematic review. Annals of Pharmacotherapy2022;56(3):309-18. [DOI: 10.1177/10600280211028242]">Murchu 2022</a> considered only preliminary data of a single study on fluvoxamine and <a href="./references#CD015391-bbs2-0051" title="LeeTC , VigodS , Bortolussi-CourvalE , HanulaR , BoulwareDR , LenzeEJ , et al. Fluvoxamine for outpatient COVID-19 to prevent hospitalization: a systematic review and meta-analysis. medRxiv. [DOI: 10.1101/2021.12.17.21268008]">Lee 2021</a> focused on unpublished data. Therefore, we aim to provide a complete evidence profile for oral fluvoxamine as a treatment for COVID‐19, in both inpatients and outpatients. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015391-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015391-sec-0014"></div> <p>To assess the efficacy and safety of fluvoxamine in addition to standard care, compared to standard care (alone or with placebo), or any other active pharmacological comparator with proven efficacy for the treatment of COVID‐19 outpatients and inpatients. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015391-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015391-sec-0015"></div> <section id="CD015391-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015391-sec-0017"> <h4 class="title">Types of studies</h4> <p>The main outline of the methods section is based on the standard template of the Cochrane Haematology review group and is in line with a series of Cochrane Reviews investigating treatments and therapies for COVID‐19 (e.g. <a href="./references#CD015391-bbs2-0049" title="KreuzbergerN , HirschC , ChaiKL , TomlinsonE , KhosraviZ , PoppM , et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825.pub2]">Kreuzberger 2021</a>; <a href="./references#CD015391-bbs2-0067" title="PoppM , StegemannM , RiemerM , Metzendorf M-I, RomeroCS , MikolajewskaA , et al. Antibiotics for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD015025. [DOI: 10.1002/14651858.CD015025]">Popp 2021a</a>; <a href="./references#CD015391-bbs2-0079" title="StroehleinJK , WallqvistJ , IannizziC , MikolajewskaA , MetzendorfMI , BenstoemC , et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD015043. [DOI: 10.1002/14651858.CD015043]">Stroehlein 2021</a>). The original review protocol for this review was registered with PROSPERO (<a href="https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=299758" target="_blank">CRD42022299758</a>) on 4 January 2022. As this review and the other reviews of the Cochrane Review series are living systematic reviews during the COVID‐19 pandemic, specific adaptations relating to the research question, including participants, interventions, comparators, outcomes, and methods may be necessary in further updates. </p> <p>To assess the efficacy and safety of fluvoxamine for the treatment of people with COVID‐19 in outpatient and inpatient settings, we included randomised controlled trials (RCTs), as this study design, if performed appropriately, provides the best evidence for experimental therapies in highly controlled therapeutic settings. We used the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015391-bbs2-0040" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2020b</a>). In addition to observational studies, non‐standard RCT designs, such as cluster‐randomised and cross‐over trials, were not eligible for the review. The latter are not appropriate in this context, since the underlying cause of COVID‐19 is an infection with the SARS‐CoV‐2 virus and the medical condition evolves over time. Furthermore, we excluded controlled non‐randomised studies of interventions, animal studies, pharmacokinetic studies, and in vitro studies. </p> <p>We included the following formats, if sufficient information was available on study design, characteristics of participants, interventions, and outcomes. </p> <p> <ul id="CD015391-list-0001"> <li> <p>Full‐text journal publications</p> </li> <li> <p>Abstract publications</p> </li> <li> <p>Preprint articles</p> </li> <li> <p>Results published in trial registries</p> </li> <li> <p>Additional personal communication with investigators, if results were available in any of the above‐listed formats </p> </li> </ul> </p> <p>We included preprints and conference abstracts to have a complete overview of the ongoing research activity, especially for tracking newly emerging studies on treatments for COVID‐19. We did not apply any limitations with respect to the length of follow‐up or language of the publication. </p> </section> <section id="CD015391-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies investigating adults with a confirmed diagnosis of COVID‐19 (with reverse transcription‐polymerase chain reaction (RT‐PCR) or antigen testing) irrespective of age, sex, ethnicity and disease severity. If studies included participants with a confirmed or suspected COVID‐19 diagnosis, we only used data for patient populations with a confirmed COVID‐19 diagnosis. In cases where data were not reported separately for participants with confirmed or suspected COVID‐19 diagnosis, we included the mixed population. The status of participants in the included studies, as well as the type of COVID‐19 diagnosis, is reported in the section Included studies. If mixed population studies contributed data to the meta‐analyses, we excluded these studies in <a href="#CD015391-sec-0044">Sensitivity analysis</a> to test the robustness of the results. </p> <p>We excluded studies that evaluated fluvoxamine for other coronavirus diseases such as SARS or MERS, or other viral diseases, such as influenza. If studies enrolled populations with, or exposed to, mixed viral diseases, we only planned to include studies if the trial authors provided subgroup data for COVID‐19. </p> </section> <section id="CD015391-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The intervention was defined as treatment with fluvoxamine. All doses and therapeutic regimes were eligible. </p> <p>We compared fluvoxamine in addition to standard care (including no intervention), to standard care (alone or with placebo), or any other active pharmacological comparator with proven efficacy (within clinical trials with a high weight of evidence) for the treatment of COVID‐19. </p> <p>For example, dexamethasone has been shown to reduce mortality from COVID‐19 amongst participants who were randomised to receive dexamethasone compared to those who received standard care (<a href="./references#CD015391-bbs2-0022" title="AgarwalA , RochwergB , LamontagneF , SiemieniukRA , AgoritsasT , AskieL , et al. A living WHO guideline on drugs for Covid-19. BMJ2020;m3379:1-14. [DOI: 10.1136/bmj.m3379]">Agarwal 2020</a>; <a href="./references#CD015391-bbs2-0070" title="RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. Respiratory medicine2021;9(12):1419-26. [DOI: 10.1016/S2213-2600(21)00435-5]">RECOVERY 2021</a>), in people who were oxygenated or received respiratory support. Remdesivir showed some benefit for people hospitalised with COVID‐19, though to a lesser extent (<a href="./references#CD015391-bbs2-0025" title="BeigelJK , TomashekKM , DoddLE , MehtaAK , ZingmanBS , KalilAC , et al. Remdesivir for the treatment of Covid-19. New England Journal of Medicine2020;383(19):1813-26. [PMID: DOI: 10.1056/NEJMoa2007764]">Beigel 2020</a>). For people who qualify for dexamethasone therapy, for instance, or for any other intervention that is proven to be beneficial in the future, it would be unethical to further conduct trials that compare an intervention to placebo only. On the contrary, studies using comparators without proven efficacy, such as hydroxychloroquine, may confound the assessment of the efficacy or safety of fluvoxamine, so we excluded these. Although these types of intervention were possibly used at certain time points during the pandemic with the best intentions, their use was never supported through the evidence, and they may also be associated with adverse effects (<a href="./references#CD015391-bbs2-0076" title="SinghB , RyanH , KredoT , ChaplinM , FletcherT . Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 2. Art. No: CD013587. [DOI: 10.1002/14651858.CD013587.pub2]">Singh 2021</a>). From those comparisons, no reliable evidence could be obtained; therefore, active comparators without proven efficacy were not eligible for this review. For the current review, we did not find any studies using an active comparator with proven efficacy. </p> <p>We excluded studies evaluating fluvoxamine in combination with other active treatments, if the same treatment was not used in the control group. We also excluded studies investigating its efficacy and safety in preventing COVID‐19. We created the following comparisons. </p> <p> <ul id="CD015391-list-0002"> <li> <p>Fluvoxamine in addition to standard care (including no intervention) versus standard care (alone or with placebo) </p> </li> <li> <p>Fluvoxamine in addition to standard care (including no intervention) versus active pharmacological intervention for the treatment of COVID‐19 with proven efficacy (no studies were available for the current review version) </p> </li> </ul> </p> </section> <section id="CD015391-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated core outcomes in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for people with COVID‐19 (<a href="./references#CD015391-bbs2-0028" title="COMET Initiative. Core outcome set developers’ response to COVID-19; April 2021. www.comet-initiative.org/Studies/Details/1538.">COMET 2021</a>; <a href="./references#CD015391-bbs2-0053" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]]">Marshall 2020</a>), and additional outcomes that have been prioritised by consumer representatives and the German guideline panel for inpatient therapy of people with COVID‐19, as well as the German Primary Care Association Guidelines (DEGAM) for the treatment of acute COVID‐19 in the outpatient setting (<a href="./references#CD015391-bbs2-0031" title="BlankenfeldH , KaduszkiewiczH , KochenMM , PömslJ , SchererM . SARS-CoV-2/Covid-19information and practical aids for established general practitioners and general practitioners (Version 22) [SARS-CoV-2/ Covid-19-Informationen &amp; Praxishilfen für niedergelassene Hausärztinnen und Hausärzte (Version 22)]. www.degam-leitlinien.de/ (accessed 16 June 2022).">DEGAM 2022</a>). The current outcome set is in alignment with the previous review in this series of Cochrane Reviews investigating the use of potential pharmacotherapies for COVID‐19 in both inpatients and outpatients (<a href="./references#CD015391-bbs2-0067" title="PoppM , StegemannM , RiemerM , Metzendorf M-I, RomeroCS , MikolajewskaA , et al. Antibiotics for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD015025. [DOI: 10.1002/14651858.CD015025]">Popp 2021a</a>). </p> <p>We defined outcome sets with primary and secondary outcomes for two populations.</p> <p> <ul id="CD015391-list-0003"> <li> <p>Inpatients (hospitalised individuals, secondary care) with moderate to severe (World Health Organization (WHO) severity score &gt; 4) (<a href="./references#CD015391-bbs2-0093" title="World Health Organization. COVID-19 Therapeutic Trial Synopsis. www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis (accessed 14 February 2022).">WHO 2020e</a> ) COVID‐19 </p> </li> <li> <p>Outpatients (ambulatory‐managed individuals, primary care) with asymptomatic or mild COVID‐19 (WHO severity score ≤ 4) (<a href="./references#CD015391-bbs2-0093" title="World Health Organization. COVID-19 Therapeutic Trial Synopsis. www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis (accessed 14 February 2022).">WHO 2020e</a>) </p> </li> </ul> </p> <p>Primary outcomes were used to inform the <a href="./full#CD015391-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD015391-sec-0021"> <h5 class="title">Timing of outcome measurement</h5> <p>We collected information on outcomes from all time points reported in the publications. If only a few studies contributed data to an outcome, we pooled different time points, provided the studies had produced valid data and pooling was clinically reasonable. </p> <p>In the case of time‐to‐event analysis, for instance as with 'time to death', we included the outcome measure based on the longest follow‐up time and measured from randomisation. </p> <p>We included serious adverse events and adverse events occurring during the study period, including both adverse events during active treatment and long‐term adverse events. If sufficient data were available, we grouped the measurement time points of eligible outcomes (e.g. adverse events and serious adverse events) into those measured directly after treatment (up to seven days after treatment), medium‐term outcomes (up to 14 days after treatment) and longer‐term outcomes (more than 28 days after treatment). </p> </section> <section id="CD015391-sec-0022"> <h5 class="title">Primary outcomes</h5> <section id="CD015391-sec-0023"> <h6 class="title">Inpatients with moderate to severe COVID‐19</h6> <p> <ul id="CD015391-list-0004"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and at hospital discharge</p> </li> <li> <p>Clinical status at day 28, day 60, and up to the longest follow‐up, including</p> <ul id="CD015391-list-0005"> <li> <p>worsening of clinical status</p> <ul id="CD015391-list-0006"> <li> <p>participants with clinical deterioration (new need for invasive mechanical ventilation) or death </p> </li> </ul> </li> <li> <p>improvement of clinical status</p> <ul id="CD015391-list-0007"> <li> <p>participants discharged alive (participants should be discharged without clinical deterioration or death) </p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. with the WHO Quality of Life‐100 (WHOQoL‐100) scale) at up to seven days; up to 28 days, and longest follow‐up available </p> </li> <li> <p>Serious adverse events during the study period</p> </li> <li> <p>Adverse events (any grade) during the study period, defined as the number of participants with any event </p> </li> </ul> </p> </section> <section id="CD015391-sec-0024"> <h6 class="title">Outpatients with asymptomatic or mild COVID‐19 (WHO &lt; 4)</h6> <p> <ul id="CD015391-list-0008"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and up to the longest follow‐up</p> </li> <li> <p>All‐cause admission to hospital or death (before hospital admission)</p> </li> <li> <p>Symptom resolution</p> <ul id="CD015391-list-0009"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14, day 28, and up to the longest follow‐up </p> </li> <li> <p>duration to symptom resolution</p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at day seven, up to day 28, and the longest follow‐up available </p> </li> <li> <p>Serious adverse events during the study period</p> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any event </p> </li> <li> <p>Suicide or suicide attempt</p> </li> </ul> </p> </section> </section> <section id="CD015391-sec-0025"> <h5 class="title">Secondary outcomes</h5> <section id="CD015391-sec-0026"> <h6 class="title">Inpatients with moderate to severe COVID‐19</h6> <section id="CD015391-sec-0027"> <p><b>Additional outcomes</b></p> <p> <ul id="CD015391-list-0010"> <li> <p>Clinical status at day 15, day 28 and up to the longest follow‐up</p> <ul id="CD015391-list-0011"> <li> <p>worsening of clinical status</p> <ul id="CD015391-list-0012"> <li> <p>need for invasive mechanical ventilation</p> </li> <li> <p>need for non‐invasive mechanical ventilation or high flow</p> </li> <li> <p>need for oxygen by mask or nasal prongs</p> </li> <li> <p>need for hospitalisation without oxygen therapy</p> </li> </ul> </li> <li> <p>improvement of clinical status</p> <ul id="CD015391-list-0013"> <li> <p>weaning or liberation from invasive mechanical ventilation in surviving patients</p> </li> <li> <p>ventilator‐free days</p> </li> <li> <p>duration to liberation from invasive mechanical ventilation</p> </li> <li> <p>liberation from supplemental oxygen in surviving patients</p> </li> <li> <p>duration to liberation from supplemental oxygen</p> </li> </ul> </li> </ul> </li> <li> <p>Need for dialysis at up to day 28</p> </li> <li> <p>Admission to the intensive care unit (ICU) at day 28</p> </li> <li> <p>Duration of hospitalisation</p> </li> <li> <p>Viral clearance, assessed with RT‐PCR test for SARS‐CoV‐2 at baseline, up to day three, day seven, and day 14 </p> </li> <li> <p>Hospital‐acquired infections up to day 28</p> </li> </ul> </p> </section> </section> <section id="CD015391-sec-0028"> <h6 class="title">Outpatients with asymptomatic or mild COVID‐19 (WHO &lt; 4)</h6> <section id="CD015391-sec-0029"> <p><b>Additional outcomes</b></p> <p> <ul id="CD015391-list-0014"> <li> <p>Clinical status at day 15, day 28 and up to the longest follow‐up</p> <ul id="CD015391-list-0015"> <li> <p>worsening of clinical status (moderate to severe COVID‐19 symptoms)</p> <ul id="CD015391-list-0016"> <li> <p>need for invasive mechanical ventilation</p> </li> <li> <p>need for non‐invasive mechanical ventilation or high flow</p> </li> <li> <p>need for hospitalisation (with need for oxygen by mask or nasal prongs)</p> </li> <li> <p>need for hospitalisation (without oxygen therapy)</p> </li> </ul> </li> </ul> </li> <li> <p>Viral clearance, assessed with RT‐PCR for SARS‐CoV‐2 at baseline, up to day three, day seven, and day 14 </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section id="CD015391-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015391-sec-0031"> <h4 class="title">Electronic searches</h4> <p>Our Information Specialist (IM) designed systematic search strategies and a second Information Specialist peer reviewed them. We searched in the following sources from the inception of each database up to 1 February 2022 and did not place restrictions on the language of the publication. </p> <p> <ul id="CD015391-list-0017"> <li> <p>Cochrane COVID‐19 Study Register (CCSR) (<a href="http://www.covid-19.cochrane.org/" target="_blank">www.covid-19.cochrane.org</a>) </p> <ul id="CD015391-list-0018"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (monthly updates)</p> </li> <li> <p>MEDLINE (PubMed) (weekly updates)</p> </li> <li> <p>Embase.com (weekly updates)</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) (daily updates) </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="https://trialsearch.who.int" target="_blank">trialsearch.who.int/</a>) (monthly updates) </p> </li> <li> <p>medRxiv (<a href="http://www.medrxiv.org/" target="_blank">www.medrxiv.org</a>) (weekly updates) </p> </li> </ul> </li> <li> <p>Web of Science Core Collection</p> <ul id="CD015391-list-0019"> <li> <p>Science Citation Index Expanded (1945 to present)</p> </li> <li> <p>Emerging Sources Citation Index (2015 to present)</p> </li> </ul> </li> <li> <p>WHO COVID‐19 Global literature on coronavirus disease (<a href="https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/" target="_blank">search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/</a>) </p> </li> </ul> </p> <p>For detailed search strategies, see <a href="./appendices#CD015391-sec-0094">Appendix 1</a>. </p> </section> <section id="CD015391-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We searched for other potentially eligible studies or ancillary publications by searching the reference lists of included studies, systematic reviews and meta‐analyses. In addition, we contacted the investigators of included studies to obtain additional information on the retrieved studies when needed. </p> </section> </section> <section id="CD015391-sec-0033"> <h3 class="title" id="CD015391-sec-0033">Data collection and analysis</h3> <section id="CD015391-sec-0034"> <h4 class="title">Selection of studies</h4> <p>In accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015391-bbs2-0052" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , MetzendorfMI , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Lefebvre 2021</a>), two review authors (JN, IT, AAT or CS) independently screened the results of the search strategies for eligibility of this review by reading the titles and abstracts using <a href="https://www.covidence.org/" target="_blank">Covidence</a>. We then retrieved full‐text articles and assessed eligibility of the remaining records against predefined eligibility criteria in duplicate. We resolved discrepancies by discussion within the group of review authors. We included studies in the review irrespective of whether the measured outcome data were reported in a ‘usable’ way. We collated multiple reports of the same study, so that the study, rather than the report, was the unit of interest in the review. </p> <p>We documented the study selection process in a flow diagram, as recommended in the PRISMA statement (<a href="./references#CD015391-bbs2-0063" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372(71):1-9. [DOI: 10.1136/bmj.n71]">Page 2021</a>), and show the total number of retrieved references and the numbers of included, ongoing, excluded studies, as well as those awaiting classification in <a href="#CD015391-fig-0001">Figure 1</a>. We listed all studies that we excluded after full‐text assessment and the reasons for their exclusion in the <a href="./references#CD015391-sec-0106" title="">Characteristics of excluded studies</a>, and used the same procedure for the <a href="./references#CD015391-bbs1-0003" title="">Studies awaiting classification</a>. </p> <div class="figure" id="CD015391-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Figure 1: PRISMA flow diagram of study selection" data-id="CD015391-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Figure 1: PRISMA flow diagram of study selection</b> </p> </div> </div> </div> </section> <section id="CD015391-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We conducted data extraction according to the guidelines proposed by Cochrane (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0139" target="_blank">Li 2020</a>). Two review authors (JN, IT or CS) extracted data independently and in duplicate, using a customised data extraction form developed in Microsoft Excel (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0145" target="_blank">Microsoft 2018</a>). We solved disagreements by discussion. If no agreement was reached, we involved a third review author to resolve the disagreement. </p> <p>We extracted the following information, if reported.</p> <p> <ul id="CD015391-list-0020"> <li> <p>General information: author, title, source, country, language, type of publication, publication date </p> </li> <li> <p>Study characteristics: setting and dates, inclusion/exclusion criteria, number of study arms, comparability of groups, treatment cross‐overs, treatment tailoring, intervention modification, length of follow‐up, funding </p> </li> <li> <p>Participant characteristics: number of participants randomised/received intervention/analysed, COVID‐19 diagnostics, severity of disease, age, gender, comorbidities (e.g. diabetes, immunosuppression), concurrent interventions, time since symptom onset </p> </li> <li> <p>Intervention: dose, frequency, duration, and route of administration</p> </li> <li> <p>Control intervention: type of control, frequency, duration, and route of administration</p> </li> <li> <p>Outcomes: as specified under <a href="#CD015391-sec-0020">Types of outcome measures</a> </p> </li> </ul> </p> </section> <section id="CD015391-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Risk of Bias 2 (RoB 2) tool to analyse the risk of bias of study results contributing information to our primary outcomes (<a href="https://www.riskofbias.info/welcome/rob-2-0-tool" target="_blank">risk of bias 2.0</a>; <a href="./references#CD015391-bbs2-0078" title="SterneJA , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:1-8. [DOI: 10.1136/bmj.l4898]">Sterne 2019</a>). Of interest for this review was the effect of the assignment to the intervention (the intention‐to‐treat (ITT) effect), so we performed all assessments with RoB 2 on this effect. The outcomes that we assessed are the primary outcomes specified for inclusion in the summary of findings tables. </p> <p>Two review authors (JN, IT) independently assessed the risk of bias for each outcome. In case of discrepancies among their judgements and inability to reach consensus, we consulted the third review author to reach a final decision. We assessed the following types of bias as outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015391-bbs2-0041" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021</a>). </p> <p> <ul id="CD015391-list-0021"> <li> <p>Bias arising from the randomisation process</p> </li> <li> <p>Bias due to deviations from the intended interventions</p> </li> <li> <p>Bias due to missing outcome data</p> </li> <li> <p>Bias in measurement of the outcome</p> </li> <li> <p>Bias in selection of the reported result</p> </li> </ul> </p> <p>To address these types of bias we used the signalling questions recommended in RoB 2 and make a judgement using the following options. </p> <p> <ul id="CD015391-list-0022"> <li> <p>'Yes': if there is firm evidence that the question is fulfilled in the study (i.e. the study is at low or high risk of bias for the given the direction of the question) </p> </li> <li> <p>'Probably yes': a judgement has been made that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question) </p> </li> <li> <p>'No': if there is firm evidence that the question is unfilled in the study (i.e. the study is at low or high risk of bias for the given the direction of the question) </p> </li> <li> <p>'Probably no': a judgement has been made that the question is unfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question) </p> </li> <li> <p>'No information': if the study report does not provide sufficient information to allow any judgement </p> </li> </ul> </p> <p>We used the algorithms proposed by RoB 2 to assign each domain one of the following levels of bias. </p> <p> <ul id="CD015391-list-0023"> <li> <p>Low risk of bias</p> </li> <li> <p>Some concerns</p> </li> <li> <p>High risk of bias</p> </li> </ul> </p> <p>Subsequently, we derived an overall risk of bias rating for each prespecified outcome in each study in accordance with the following suggestions. </p> <p> <ul id="CD015391-list-0024"> <li> <p>'Low risk of bias': we judged the trial to be at low risk of bias for all domains for this result </p> </li> <li> <p>'Some concerns': we judged the trial to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain </p> </li> <li> <p>'High risk of bias': we judged the trial to be at high risk of bias in at least one domain for the result, or we judged the trial to have some concerns for multiple domains in a way that substantially lowers confidence in the results </p> </li> </ul> </p> <p>To implement RoB 2, we used the RoB 2 Excel tool (available on the website <a href="https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2" target="_blank">www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2</a>), and stored and presented our detailed RoB 2 assessments in the analyses section. </p> </section> <section id="CD015391-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we recorded the number of events and total number of participants in both treatment and control groups and reported the pooled risk ratio (RR) with 95% confidence intervals (CIs) and the risk difference (RD) (<a href="./references#CD015391-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). </p> <p>For continuous outcomes, we recorded the mean, standard deviation and total number of participants in both treatment and control groups. Where continuous outcomes used the same scale, we performed analyses using the mean difference (MD) with 95% CIs (<a href="./references#CD015391-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). For continuous outcomes measured with different scales, we planned to perform analyses using the standardised mean difference (SMD) (<a href="./references#CD015391-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). For interpreting SMDs, we planned to re‐express SMDs in the original units of a particular scale with the most clinical relevance and impact. For the current review, all outcomes were measured on comparable scales. </p> <p>If available, we extracted and reported hazard ratios (HRs) for time‐to‐event outcomes (e.g. time to hospital discharge). If HRs were not available, we would have made every effort to estimate the HR as accurately as possible from available data using the methods proposed by Parmar and Tierney (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0152" target="_blank">Parmar 1998</a>; <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0170" target="_blank">Tierney 2007</a>). If sufficient studies provided HRs, we would have used HRs rather than RRs or MDs in a meta‐analysis, as HRs provide more information. </p> </section> <section id="CD015391-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis for this review is the individually‐randomised participant. In studies with multiple intervention groups, we followed the recommendations in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015391-bbs2-0039" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020. Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Higgins 2020a</a>). For studies with multiple treatment groups of the same intervention (i.e. dose, route of administration), we combined the study arms if they were sufficiently homogeneous. If arms could not be pooled, which was not the case for the current review, we had planned to compare each arm with the common comparator separately. For pairwise meta‐analysis, we had planned to split the ‘shared’ group into two or more groups with smaller sample size, and include two or more (independent) comparisons. For this purpose, in the case of dichotomous outcomes, we would have divided both the number of events and the total number of participants. For continuous outcomes, we would have divided the total number of participants and retained unchanged means and standard deviations (SDs). </p> </section> <section id="CD015391-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>There are many potential sources of missing data in a systematic review or meta‐analysis, which can affect the level of studies, outcomes, summary data, individuals, or study‐level characteristics (<a href="./references#CD015391-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). Incomplete data can introduce bias into the meta‐analysis if they are not missing at random, which is addressed in the section <a href="#CD015391-sec-0036">Assessment of risk of bias in included studies</a>. </p> <p>First, when data were missing at outcome and study level, we checked for any evidence for the data being missing at random. When we could not retrieve information about data being missing at random, we contacted principal investigators and requested these data (<a href="#CD015391-tbl-0002">Table 1</a>). If, after this, data were still missing, we would have assumed that data were not missing at random. On the other hand, if there were indications that data were not missing at random, we would have conducted complete case analysis for the primary analysis and would have discussed its potential impact in the discussion section. If we were concerned regarding missing data across studies, we would not have performed meta‐analyses, but would have provided subtotals per study. </p> <div class="table" id="CD015391-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Author communication</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Date of request and question of the authors' of this review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Date when feedback was received and author response provided</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 June 2022: Question regarding the outcome 'all‐cause hospitalisation', which is mentioned in the primary study, but definite numerical data were missing. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 June 2022: Numbers for all‐cause hospitalisation: 1 participant in the fluvoxamine and 5 participants in the placebo group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 January 2022: Question regarding the outcome 'symptom resolution' which is mentioned in the primary study, but definite numerical data are not reported. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Feedback was not provided.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Communications are listed after considering communication date</p> </div> </div> </section> <section id="CD015391-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the descriptive statistics reported in the <a href="./references#CD015391-sec-0105" title="">Characteristics of included studies</a> to assess whether the studies within each pairwise comparison were homogenous enough, with respect to study and intervention details and population baseline characteristics, that the assumption of homogeneity might be plausible. In case of excessive clinical heterogeneity, we did not pool the findings of included studies.<br/>We measured statistical heterogeneity using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic (<a href="./references#CD015391-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>), and the 95% prediction interval (PI) for random‐effects meta‐analysis (<a href="./references#CD015391-bbs2-0044" title="IntHoutJ , IoannidisJP , RoversMM , GoemanJJ . Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open2016;6(7):e010247. [DOI: 10.1136/bmjopen-2015-010247]">IntHout 2016</a>). The prediction interval helps in the clinical interpretation of heterogeneity by estimating what true treatment effects can be expected in future settings (<a href="./references#CD015391-bbs2-0044" title="IntHoutJ , IoannidisJP , RoversMM , GoemanJJ . Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open2016;6(7):e010247. [DOI: 10.1136/bmjopen-2015-010247]">IntHout 2016</a>). </p> <p>We restricted the calculation of a 95% PI to meta‐analyses with four or more studies (≥ 200 participants), since the interval would be imprecise if a summary estimate were based on only a few small studies. We planned to use the open‐source statistical software R package <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0144" target="_blank">Meta</a> to calculate 95% PIs, and declare statistical heterogeneity if the P value was less than 0.1 for the Chi<sup>2</sup> statistic, or the I<sup>2</sup> statistic was 40% or more (40% to 60%: moderate heterogeneity; 50% to 90%: substantial heterogeneity; 75% to 100%: considerable heterogeneity) (<a href="./references#CD015391-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>); or the range of the 95% PI revealed a different clinical interpretation of the effect estimate compared to the 95% CI. </p> </section> <section id="CD015391-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We sought to identify all research that meets our predefined eligibility criteria. Missing studies can introduce bias to the analysis. We searched for completed non‐published trials in trials registers, contacted authors to seek assurance that the results will be made available, and classified them as 'awaiting classification' until the results are reported. We reported the number of completed non‐published trials.<br/>We planned to investigate the risk of reporting bias (publication bias) in pairwise meta‐analyses using contour‐enhanced funnel plots, when there were 10 or more relevant studies pooled in a meta‐analysis. In the current review, there are no meta‐analyses including 10 or more studies. For future review updates, if funnel plot asymmetry is suggested by a visual assessment, we plan to perform exploratory analyses (e.g. Ruecker’s arcsine test for dichotomous data and Egger’s linear regression test for continuous data) to further investigate funnel plot asymmetry (<a href="./references#CD015391-bbs2-0032" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMID: 9310563]">Egger 1997</a>). A P value of less than 0.1 will be considered as the level of statistical significance. In future review updates, we will analyse reporting bias using the open‐source statistical software R package <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0144" target="_blank">Meta</a>. </p> </section> <section id="CD015391-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We analysed trials including different severities of disease separately, grouping them into asymptomatic to mild, and moderate to severely ill, as these are different populations in different settings, resulting in different outcome sets (see <a href="#CD015391-sec-0020">Types of outcome measures</a>). We analysed trials with the following participant populations separately. </p> <p> <ul id="CD015391-list-0025"> <li> <p>Inpatients with moderate to severe COVID‐19</p> </li> <li> <p>Outpatients with asymptomatic or mild COVID‐19</p> </li> </ul> </p> <p>For these two distinct populations, we created the following comparisons.</p> <p> <ul id="CD015391-list-0026"> <li> <p>Fluvoxamine in addition to standard care versus standard care (alone or with placebo)</p> </li> <li> <p>Fluvoxamine in addition to standard care versus active pharmacological intervention for the treatment of COVID‐19 with proven efficacy in clinical trials with a high weight of evidence (no studies were available for the current review version) in addition to standard care </p> </li> </ul> </p> <p>Placebo and standard care alone (including no intervention) were treated as the same intervention, as well as standard care at different institutions and time points during the pandemic. </p> <p>We performed meta‐analyses according to the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015391-bbs2-0030" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). If clinical and methodological characteristics of individual studies were sufficiently homogeneous, we pooled the data into meta‐analyses. We used the RevMan Web software for meta‐analyses (<a href="./references#CD015391-bbs2-0071" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available from revman.cochrane.org.">RevMan Web 2022</a>). One review author entered the data in the software, and a second review author checked the data for accuracy. When meta‐analysis was feasible, we used the random‐effects model as we assumed that the intervention effects were related but were not the same for the included studies. For dichotomous outcomes, we performed meta‐analyses using the Mantel‐Haenszel method under a random‐effects model to calculate the summary (combined) intervention effect estimate as a weighted average of the intervention effects estimated in the individual studies. For continuous outcomes, we used the inverse‐variance method. </p> <p>We planned to present descriptive statistics only if we deemed meta‐analysis inappropriate for a certain outcome because of heterogeneity or because of serious study limitations leading to a considerably high risk of bias (e.g competing risk of death not taken into account in outcome measurements). This was not the case for the current review version. </p> <p>If meta‐analysis was possible, we assessed the effects of potential biases in sensitivity analyses (see <a href="#CD015391-sec-0044">Sensitivity analysis</a>) and considered investigating heterogeneity in subgroup analyses (see <a href="#CD015391-sec-0043">Subgroup analysis and investigation of heterogeneity</a>). Subgroup analyses were not possible due to the low number of studies per outcome. For future review updates, if we cannot find a cause for the heterogeneity, we will not undertake a meta‐analysis but will comment instead on the results as a narrative and present the results from all studies in tables. </p> <p>We used forest plots to visualise meta‐analyses of primary outcomes only, including risk of bias assessment. We reported secondary outcomes without risk of bias assessments in additional tables. </p> </section> <section id="CD015391-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned subgroup analyses to investigate clinical heterogeneity for the following characteristics (considering primary outcomes): </p> <p> <ul id="CD015391-list-0027"> <li> <p>Disease severity at baseline as defined by the WHO Clinical Progression Scale (mild, moderate, severe) </p> </li> <li> <p>Dose of fluvoxamine (usual dose versus low dose versus high dose)</p> </li> </ul> </p> <p>In the current review version, none of these analyses were possible due to a lack of data and trials (only two included studies). </p> <p>If enough studies are identified during future review updates, we will also perform subgroup analyses, if statistical heterogeneity is present (P &lt; 0.1 for the Chi<sup>2</sup> test of heterogeneity, I<sup>2</sup> ≥ 50%), or a different clinical conclusion (when comparing 95% CI with 95% PI). We also plan to undertake tests for interaction to test for differences between subgroup results. </p> </section> <section id="CD015391-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses of the following characteristics (considering primary outcomes). </p> <p> <ul id="CD015391-list-0028"> <li> <p>Risk of bias assessment (only trials with a low risk of bias or some concerns)</p> </li> <li> <p>Comparison of preprint articles versus peer‐reviewed publications (only trials published as journal articles) </p> </li> <li> <p>Confirmed versus mixed (suspected and confirmed) COVID‐19 diagnosis (only trials/participants with confirmed COVID‐19 diagnosis) </p> </li> </ul> </p> <p>Similar to the subgroup analyses, such analyses were not possible in the current review version (due to the low number of trials). </p> </section> <section id="CD015391-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD015391-sec-0046"> <h5 class="title">Summary of findings</h5> <p>We evaluated the certainty of the evidence using the GRADE approach for the interventions evaluated in RCTs. </p> <p>We planned to create a separate summary of findings tables for the different patient populations (outpatients, inpatients) and for the different comparisons. For the current review version, there were no studies addressing inpatients or an active comparator. </p> <p>We used the <a href="./references#CD015391-bbs2-0036" title="GRADEpro GDT. Version accessed 15 August 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a> to create a summary of findings table. For time‐to‐event outcomes, we planned to calculate absolute effects at specific time points, as recommended in the GRADE guidance 27 (<a href="./references#CD015391-bbs2-0077" title="SkoetzN , GoldkuhleM , Van DalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles. Journal of Clinical Epidemiology2020;118:124-31. [DOI: 10.1016/j.jclinepi.2019.10.015]">Skoetz 2020</a>). For the current review, there were no time‐to‐event data available. According to Chapter 14 of the updated <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, the “most critical and/or important health outcomes, both desirable and undesirable, limited to seven or fewer outcomes” should be included in the summary of findings table (<a href="./references#CD015391-bbs2-0075" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Schünemann 2020</a>). We included the following outcomes prioritised according to the Core Outcome Set for intervention studies (<a href="./references#CD015391-bbs2-0028" title="COMET Initiative. Core outcome set developers’ response to COVID-19; April 2021. www.comet-initiative.org/Studies/Details/1538.">COMET 2021</a>, <a href="./references#CD015391-bbs2-0053" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]]">Marshall 2020</a>) and patient relevance. </p> <section id="CD015391-sec-0047"> <h6 class="title">Inpatients with moderate to severe COVID‐19</h6> <p> <ul id="CD015391-list-0029"> <li> <p>All‐cause mortality (most favourable time point: at hospital discharge, if not reported for this time point we considered day 60, followed by day 28, or time‐to‐event estimate) </p> </li> <li> <p>Worsening of clinical status at day 28</p> <ul id="CD015391-list-0030"> <li> <p>participants with clinical deterioration (new need for invasive mechanical ventilation) or death </p> </li> </ul> </li> <li> <p>Improvement of clinical status at day 28</p> <ul id="CD015391-list-0031"> <li> <p>participants discharged alive</p> </li> </ul> </li> <li> <p>Quality of life at longest follow‐up available</p> </li> <li> <p>Serious adverse events during the study period</p> </li> <li> <p>Any adverse events during the study period</p> </li> <li> <p>Suicide or suicide attempt</p> </li> </ul> </p> </section> <section id="CD015391-sec-0048"> <h6 class="title">Outpatients with asymptomatic or mild COVID‐19</h6> <p> <ul id="CD015391-list-0032"> <li> <p>All‐cause mortality (most favourable at longest follow‐up (&gt; 60 days), if not reported at longest follow‐up we considered day 60, followed by day 28, or time‐to‐event estimate) </p> </li> <li> <p>Admission to hospital (all cause) or death (combined outcome, within 28 days)</p> </li> <li> <p>Symptom resolution</p> <ul id="CD015391-list-0033"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14</p> </li> <li> <p>duration to symptom resolution</p> </li> </ul> </li> <li> <p>Quality of life at longest follow‐up available</p> </li> <li> <p>Serious adverse events during the study period</p> </li> <li> <p>Any adverse events during the study period</p> </li> <li> <p>Suicide or suicide attempt</p> </li> </ul> </p> </section> </section> <section id="CD015391-sec-0049"> <h5 class="title">Assessment of certainty in the evidence</h5> <p>We used the GRADE approach to assess the certainty in the evidence for the outcomes listed above. The GRADE approach uses five domains (risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty in the body of evidence for each prioritised outcome. </p> <p>We downgraded our certainty of evidence as follows.</p> <p> <ul id="CD015391-list-0034"> <li> <p>Serious (‐1) or very serious (‐ 2) risk of bias</p> </li> <li> <p>Serious (‐1) or very serious (‐ 2) inconsistency</p> </li> <li> <p>Serious (‐1) or very serious (‐ 2) uncertainty about directness</p> </li> <li> <p>Serious (‐1) or very serious (‐ 2) imprecise or sparse data</p> </li> <li> <p>Serious (‐1) or very serious (‐ 2) probability of reporting bias</p> </li> </ul> </p> <p>The GRADE system used the following criteria for assigning grade of evidence.</p> <p> <ul id="CD015391-list-0035"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We followed the current GRADE guidance for these assessments in its entirety as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapter 14 (<a href="./references#CD015391-bbs2-0075" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Schünemann 2020</a>). We used the overall risk of bias judgement, derived from the RoB 2 Excel tool, to inform our decision on downgrading for risk of bias. We phrased the findings and certainty in the evidence as suggested in the informative statement guidance (<a href="./references#CD015391-bbs2-0074" title="SantessoN , GlentonC , DahmP , GarnerP , AklA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35. [DOI: 10.1016/j.jclinepi.2019.10.014]">Santesso 2020</a>). </p> </section> <section id="CD015391-sec-0050"> <h5 class="title">Methods for future updates (living systematic review considerations)</h5> <p>Our information specialists (IM, KG) will provide us with new search records each week, which two review authors will screen, extract, evaluate, and integrate following the guidance for Cochrane living systematic reviews (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-bbs2-0117" target="_blank">Cochrane LSR</a>). We will also manually check platform trials that were previously identified and listed as <a href="./references#CD015391-bbs1-0003" title="">Studies awaiting classification</a> for additional relevant treatment arms. </p> <p>We will wait until the accumulating evidence changes our conclusions of the implications of research and practice before republishing the review. We will consider one or more of the following components to inform this decision. </p> <p> <ul id="CD015391-list-0036"> <li> <p>The findings of one or more prioritised outcomes</p> </li> <li> <p>The credibility (e.g. GRADE rating) of one or more prioritised outcomes</p> </li> <li> <p>New settings, populations, interventions, comparisons or outcomes studied</p> </li> </ul> </p> <p>In case of emerging policy relevance because of global controversies on the intervention, we will consider republishing an update the review even though our conclusions will remain unchanged. We will review the review scope and methods approximately monthly, or more frequently if appropriate, in light of potential changes in COVID‐19 research (for example, when additional comparisons, interventions, subgroups or outcomes, or new review methods become available). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015391-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015391-sec-0051"></div> <section id="CD015391-sec-0052"> <h3 class="title">Description of studies</h3> <section id="CD015391-sec-0053"> <h4 class="title">Results of the search</h4> <p>The literature search resulted in 94 records. No records were identified via additional searches of reference lists. After removing duplicates, 86 records remained. During title and abstract screening, we judged 63 records to be irrelevant. </p> <p>We proceeded to full‐text screening with 23 records, considering published full texts or, if these were not available, trial register entries. From these 23 records, we excluded 12 records: one record (one study) was cancelled before starting patient recruitment and 11 records (11 studies) were not RCTs. From the 11 records (nine studies) that we considered to be relevant (included), five records referred to ongoing studies and two are awaiting classification. Finally, we included two studies (four records) in our quantitative synthesis, contributing data to the primary and secondary outcomes of this review. The flow of records is illustrated in <a href="#CD015391-fig-0001">Figure 1</a>. </p> </section> <section id="CD015391-sec-0054"> <h4 class="title">Inpatients</h4> <p>We did not include any clearly‐eligible, completed studies that investigated fluvoxamine in the inpatient setting. </p> <section id="CD015391-sec-0055"> <h5 class="title">Studies awaiting classification</h5> <p>We considered one study conducted in the inpatient setting to be relevant (<a href="./references#CD015391-bbs2-0073" title="SafaM , HashemianMR , AbediM , MalekMM . Effect of fluvoxamine medicine on cytokine level of COVID-19 patients, hospitalized in ICU ward [تأثیر داروی فلووکسامین بر سطح سیتوکین بیماران مبتال به9-COVID بستری در بخش ICU]. Journal of Medical Council of Iran2020;30(3):135-8. [URL: jmciri.ir/browse.php?a_code=A-10-1-2643&amp;sid=1&amp;slc_lang=en]">Safa 2020</a>), and listed this study in the section <a href="./references#CD015391-bbs1-0003" title="">Studies awaiting classification</a>. This study was only available in the Persian language, and we will re‐evaluate it once the study authors have clarified some translation issues. </p> </section> <section id="CD015391-sec-0056"> <h5 class="title">Ongoing studies</h5> <p>The characteristics of ongoing studies are available in the section <a href="./references#CD015391-bbs1-0004" title="">Ongoing studies</a>. In the inpatient setting, we identified one ongoing study (<a href="./references#CD015391-bbs2-0059" title="NCT04718480. Fluvoxamine administration in moderate SARS-CoV-2 (COVID-19) infected patients. clinicaltrials.gov/ct2/show/NCT04718480 (first received 22 January 2021).">NCT04718480</a>). This trial is still active and compares fluvoxamine with placebo treatment (both in addition to standard care) in people hospitalised with COVID‐19. The expected completion date is December 2022. The trial records refer to a planned sample size of 100. </p> </section> </section> <section id="CD015391-sec-0057"> <h4 class="title">Outpatients</h4> <section id="CD015391-sec-0058"> <h5 class="title">Study design and publication status</h5> <p>Details of the included studies are available in the section <a href="./references#CD015391-sec-0105" title="">Characteristics of included studies</a>. </p> <p>We included two randomised controlled trials in this review with a total of 1649 allocated participants, of whom 821 were allocated to fluvoxamine in addition to standard care and 828 to placebo and standard care (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> was a randomised, adaptive platform trial to investigate the efficacy of different repurposed treatments for non‐hospitalised people with COVID‐19, allocating 1497 participants to the comparison of interest. <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> allocated 152 participants in total. </p> <p>The study by <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> was performed as a remote outpatient trial and the <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> study used both in‐person and remote follow‐up assessments (i.e. relying on physical examination or self‐assessments via phone contact or video calls). Both studies were multicentric: <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> was performed in two centres in the greater St. Louis metropolitan area, USA, while the <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> study was conducted at 11 clinical sites in Brazil. With regard to equity, applicability, and resources, we must highlight that one of the included studies was performed in a high‐income country while the other was performed in an upper‐middle‐income country. Both studies reported information about the responsible ethics committee and financial support. <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> was supported by FastGrants and the Rainwater Foundation, while <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> was supported by the Taylor Family Institute for Innovative Psychiatric Treatment at Washington University and the COVID‐19 Early Treatment Fund, the Center for Brain Research in Mood Disorders at Washington University, the Bantly Foundation, and a grant from the National Institutes of Health. In both studies, a number of co‐authors reported conflicts of interests. </p> <p>Both trials were peer‐reviewed publications in indexed journals and were prospectively registered. </p> </section> <section id="CD015391-sec-0059"> <h5 class="title">Participants</h5> <p>Both studies recruited participants from the outpatient setting. <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> used an electronic health record system, physician referrers, doctors' hotlines, COVID‐19 Test Centres, Emergency Rooms (microbiology lab) as per the Healthy Mind Lab website (<a href="https://www.healthymind.wustl.edu" target="_blank">www.healthymind.wustl.edu</a>), flyers, and email notifications. <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> recruited participants at community health facilities (emergency settings, influenza‐symptom referral centres, or primary care community centres), with the help of notices through physical and social media as per local public health authorities. </p> <p>In <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>, all participants had a polymerase chain reaction (PCR)‐confirmed SARS‐CoV‐2 infection, while in <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> PCR for SARS‐CoV‐2 was not mandatory and participants were also included in the study if they had a positive rapid test for SARS‐CoV‐2 antigen done after obtaining informed consent. </p> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> performed randomisation and start of study medication within seven days of symptom onset, without further specification. In <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>, all patients had symptoms beginning within seven days of the screening date: 42.6% within the first three days of symptom onset and 34.5% between days four and seven. For the remaining participants, information on the duration of symptoms within the first seven days was missing. </p> <p>In both studies, all participants were symptomatic adults. In <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> the median age of participants was 46 years in the intervention group and 45 years in the control group (interquartile range (IQR) 35 to 58 and 36 to 54 years, respectively). In <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> the median age of participants was 50 years (IQR 39 to 56) in the intervention group and 49 years (IQR 38 to 56) in the control group. In total, 50.9% of all participants in this study were less than 50 years old. The majority of participants were female (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>: 71.7%; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>: 58.7%). </p> <p>The most common comorbidities in <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> were asthma (21%) and hypertension (19%) in the intervention group and hypertension (21%) in the control group. In <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> the most common risk factors were uncontrolled hypertension (in 14% of participants in the intervention group and 12% of participants in the control group) and type 2 diabetes mellitus (in 14% of participants in the intervention group and 12% of participants in the control group). </p> <p>The most common symptoms of COVID‐19 in <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> were loss of sense of smell (in 33% of participants in the intervention group and 25% of participants in the control group) and fatigue (in 21% of participants in the intervention group and 25% of participants in the control group). <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> did not report the details of baseline symptoms. </p> </section> <section id="CD015391-sec-0060"> <h5 class="title">Interventions and comparators</h5> <p>Both studies compared fluvoxamine in addition to standard care with placebo and standard care (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). In <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> the dose of fluvoxamine (capsules manufactured by Apotex) was titrated from 50 mg on the day of randomisation to 100 mg twice daily on days two and three and finally 100 mg three times daily on the remaining days up to day 15. After the completion of 15 days of fluvoxamine or placebo, participants were given the option to receive a six‐day open‐label course of fluvoxamine. This was a change from the original study protocol, but no data collection was conducted for this phase. Matching placebo gelatin capsules contained microcrystalline cellulose and silica gel, micronised. All active drug and placebo preparations were performed by the same pharmacy. In <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> participants were randomly assigned to fluvoxamine (manufactured by Abbott) at a dose of 100 mg twice daily for 10 days or a corresponding placebo starting directly after randomisation. Neither study specified the placebo. </p> <p>In the <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> study, standard care typically focused on the management of symptoms and provision of antipyretics, while antibiotics were provided when clinicians suspected bacterial pneumonia. <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> did not report standard care, and the participants received either fluvoxamine or placebo during quarantine. However, taking immunosuppressant biological drugs or high‐dose corticosteroids (&gt; 20 mg/d of prednisone) were exclusion criteria in the <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> study. <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> did not allow current use of an SSRI. </p> </section> <section id="CD015391-sec-0061"> <h5 class="title">Outcome measures</h5> <p>The primary outcome in <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> was clinical deterioration, defined by meeting both criteria of (1) shortness of breath or hospitalisation for shortness of breath or pneumonia and (2) oxygen saturation &lt; 92% on room air or need for supplemental oxygen to achieve oxygen saturation of 92% or greater (within 15 days). The primary outcome in <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> was admission to hospital, defined as COVID‐19 emergency setting visits (participants remaining under observation for over six hours) or admission to hospitalisation due to progression of COVID‐19 (within 28 days). </p> <p>Secondary outcomes included in <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> were 30 days of post‐trial observation events (emergency department visit, hospitalisation, or both) and ventilator support. All outcomes were measured using participants’ self‐reported responses on twice‐daily surveys during the 15 days after randomisation and assessed remotely (via Zoom videoconference, phone, text, email, as well as REDCap surveys pushed out to participants via their smartphones or other devices). In order to standardise the procedure, criteria were formulated for which an emergency department visit was indicated (a decrease in oxygen saturation &lt; 90% on room air on more than two readings, persistent increase in respiratory rate to &gt; 30 breaths per minute, persistent increase in heart rate to &gt; 120 beats per minute, alteration in mentation, or severe worsening in shortness of breath). At 30 days after the conclusion of the 15‐day trial, a follow‐up survey was performed by phone, email, or electronic medical record review. In the follow‐up, the participants were asked if they were hospitalised or had visited a hospital or emergency department since the last study survey. </p> <p>In <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>, secondary outcomes included time to clinical improvement, number of days with respiratory symptoms, time to hospitalisation (for any cause or due to COVID‐19 progression), length of hospitalisation (days), proportion of participants with mechanical ventilation, time on mechanical ventilator (days), proportion of participants who were non‐adherent with the study drugs, and adverse reactions to the study medications. Study personnel collected outcome data on days one, two, three, four, five, seven, ten, 14, and 28 in‐person or via telephone or social media using video‐teleconferencing. At the baseline visit, a six‐lead electrocardiogram (Kardiamobile, Mountain View, CA, USA) was performed for all participants and transferred to a central facility (Cardresearch, Belo Horizonte, Brazil) for reading. Vital signs included oxygen status assessed by means of a pulse oximeter for non‐invasive arterial oxygen saturation and pulse (Jumper Medical Equipment, Shenzhen, China), and temperature by a standard digital oral thermometer. </p> </section> <section id="CD015391-sec-0062"> <h5 class="title">Studies awaiting classification</h5> <p>We considered one study conducted in the outpatient setting to be relevant (<a href="./references#CD015391-bbs2-0058" title="NCT04668950. Fluvoxamine for early treatment of Covid-19 (Stop Covid 2). clinicaltrials.gov/ct2/show/NCT04668950 (first received 16 December 2020).">NCT04668950</a>), and listed it in the section <a href="./references#CD015391-bbs1-0003" title="">Studies awaiting classification</a>. Although the study is related to the included and published study of <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> (but conducted across the United States and two provinces of Canada), we have not yet identified any published reports. </p> </section> <section id="CD015391-sec-0063"> <h5 class="title">Ongoing Studies</h5> <p>The characteristics of ongoing studies in outpatients are available in the section <a href="./references#CD015391-bbs1-0004" title="">Ongoing studies</a>. We classified four trials as ongoing: three are still active and are currently recruiting (<a href="./references#CD015391-bbs2-0057" title="NCT04510194. COVID-OUT: early outpatient treatment for SARS-CoV-2 infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04510194 (first received 12 August 2020).">NCT04510194</a>; <a href="./references#CD015391-bbs2-0060" title="NCT04885530. ACTIV-6: COVID-19 outpatient randomized trial to evaluate efficacy of repurposed medications. clinicaltrials.gov/ct2/show/NCT04885530 (first received on 13 May 2021).">NCT04885530</a>; <a href="./references#CD015391-bbs2-0061" title="NCT05087381. Randomized-controlled trial of the effectiveness of COVID-19 early treatment in community. clinicaltrials.gov/ct2/show/record/NCT05087381 (first received 21 October 2021).">NCT05087381</a>), while the other trial (<a href="./references#CD015391-bbs2-0083" title="TCTR20210615002. Effect of combined fluvoxamine with favipiravir versus favipiravir monotherapy in prevention of clinical deterioration among mild to moderate COVID-19 patients monitoring by telemedicine in virtual clinic: open-label randomized controlled trial. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20210615002 (first received 14 June 2021). [CENTRAL: CN-02281273]">TCTR20210615002</a>) is pending (not yet recruiting). In all trials, fluvoxamine is being compared to placebo or standard care or with other pharmacological interventions in the outpatient setting. Ongoing studies are evaluating participants aged 18 years and older. The original completion date for the <a href="./references#CD015391-bbs2-0083" title="TCTR20210615002. Effect of combined fluvoxamine with favipiravir versus favipiravir monotherapy in prevention of clinical deterioration among mild to moderate COVID-19 patients monitoring by telemedicine in virtual clinic: open-label randomized controlled trial. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20210615002 (first received 14 June 2021). [CENTRAL: CN-02281273]">TCTR20210615002</a> trial was December 2021, and the expected completion date for <a href="./references#CD015391-bbs2-0061" title="NCT05087381. Randomized-controlled trial of the effectiveness of COVID-19 early treatment in community. clinicaltrials.gov/ct2/show/record/NCT05087381 (first received 21 October 2021).">NCT05087381</a> was March 2022, while those for <a href="./references#CD015391-bbs2-0060" title="NCT04885530. ACTIV-6: COVID-19 outpatient randomized trial to evaluate efficacy of repurposed medications. clinicaltrials.gov/ct2/show/NCT04885530 (first received on 13 May 2021).">NCT04885530</a> and <a href="./references#CD015391-bbs2-0057" title="NCT04510194. COVID-OUT: early outpatient treatment for SARS-CoV-2 infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04510194 (first received 12 August 2020).">NCT04510194</a> are in early 2023. These four trial records refer to planned sample sizes of 296 (<a href="./references#CD015391-bbs2-0083" title="TCTR20210615002. Effect of combined fluvoxamine with favipiravir versus favipiravir monotherapy in prevention of clinical deterioration among mild to moderate COVID-19 patients monitoring by telemedicine in virtual clinic: open-label randomized controlled trial. trialsearch.who.int/Trial2.aspx?TrialID=TCTR20210615002 (first received 14 June 2021). [CENTRAL: CN-02281273]">TCTR20210615002</a>), 1350 (<a href="./references#CD015391-bbs2-0057" title="NCT04510194. COVID-OUT: early outpatient treatment for SARS-CoV-2 infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04510194 (first received 12 August 2020).">NCT04510194</a>), 1800 (<a href="./references#CD015391-bbs2-0061" title="NCT05087381. Randomized-controlled trial of the effectiveness of COVID-19 early treatment in community. clinicaltrials.gov/ct2/show/record/NCT05087381 (first received 21 October 2021).">NCT05087381</a>), and 15000 (<a href="./references#CD015391-bbs2-0060" title="NCT04885530. ACTIV-6: COVID-19 outpatient randomized trial to evaluate efficacy of repurposed medications. clinicaltrials.gov/ct2/show/NCT04885530 (first received on 13 May 2021).">NCT04885530</a>), respectively. </p> </section> </section> <section id="CD015391-sec-0064"> <h4 class="title">Excluded studies</h4> <p>We excluded 12 records after full‐text assessment, and these are listed in the section <a href="./references#CD015391-bbs1-0002" title="">Excluded studies</a>. One record (one study) was cancelled before starting participant recruitment and 11 records (11 studies) were not RCTs. </p> </section> </section> <section id="CD015391-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed methodological quality and risk of bias for two RCTs contributing results to our primary outcomes using the RoB 2 tool. The RoB 2 judgements for all study results per outcome and for all domains are available in an interactive risk of bias table (<a href="./references#CD015391-tblf-0011" title="">Risk of bias table for Analysis 1.1</a>; <a href="./references#CD015391-tblf-0012" title="">Risk of bias table for Analysis 1.2</a>; <a href="./references#CD015391-tblf-0013" title="">Risk of bias table for Analysis 1.3</a>; <a href="./references#CD015391-tblf-0014" title="">Risk of bias table for Analysis 1.4</a>) and are briefly summarised below. </p> <section id="CD015391-sec-0066"> <h4 class="title">Overall risk of bias by study</h4> <p>We assessed both studies to have an overall high risk of bias (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>), mainly due to concerns with the outcome measurement (mostly self‐reported outcomes collected remotely), and due to missing participant data. In <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>, 20% of study participants stopped responding to surveys during the 15‐day trial. The possibility that some of these participants (n = 6) received care at an urgent care centre outside the trial could not be excluded. For 31 participants, it was confirmed that they did not receive any medical care for worsening of COVID‐19. </p> </section> <section id="CD015391-sec-0067"> <h4 class="title">Overall risk of bias by outcome</h4> <p>The following section summarises the risk of bias per outcome for all primary outcomes included in the summary of findings table (<a href="./full#CD015391-tbl-0001">summary of findings Table 1</a>.) </p> <p>We have no concerns regarding the risk of bias across studies for the outcome 'all‐cause mortality at day 28'. We identified a high risk of bias due to missing outcome data for one trial that contributed data to this outcome (18 out of 80 (22.5%) in the intervention group and 19 out of 72 (26.4%) in the placebo group did not complete the study and reasons for missing data were not provided) (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>). However, this study did not impact the result of the analysis (zero event study, <a href="./references#CD015391-fig-0002" title="">Analysis 1.1</a>), so we based the bias summary on <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>, where the dropout rate was less than 12%. </p> <p>We also have no concerns regarding risk of bias for the outcome 'admission to hospital and death' reported by one study (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). Although hospital admission rates may be more frequent in trials with a remote patient assessment, particularly when patients are diagnosed with an infectious disease, and direct (face‐to‐face) contact with a clinician is lacking, the randomised allocation of participants should balance this issue between study arms. </p> <p>For 'serious adverse events' and 'adverse events', we also identified a high risk of bias due to the measurement of the outcome. All (serious and non‐serious) adverse events appear to be self‐reported, and it is unclear whether they were verified by medical records or practitioner reports, which may be associated with an under‐ or overestimation of such events. Furthermore, the results could be impacted due to missing participant data, particularly in the study of <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>. </p> </section> </section> <section id="CD015391-sec-0068"> <h3 class="title" id="CD015391-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD015391-tbl-0001"><b>Summary of findings 1</b> Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</a> </p> <p>on time to ssssAs we did not include any studies investigating efficacy and safety of fluvoxamine in the inpatient setting, this section effectively only addresses the outpatient setting. </p> <p>Primary outcomes are displayed in the summary of findings table (<a href="./full#CD015391-tbl-0001">summary of findings Table 1</a> 'Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19'). </p> <p>We included two placebo‐controlled studies in both qualitative synthesis and quantitative synthesis (meta‐analysis) of this review (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). Both studies investigated outpatients with confirmed mild COVID‐19. </p> <p>We did not conduct sensitivity analysis regarding the risk of bias, since only one study had a low risk of bias for the outcome 'all‐cause mortality' (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> did not report any events reported for this outcome. So the study with a low risk of bias contributed 100% to the weight of the meta‐analysis. </p> <p>There were no indications of data not missing at random, so predefined analyses for such cases were not applicable. </p> <p>In the current review, there are not enough studies available to perform the planned subgroup analyses to investigate heterogeneity for study characteristics (such as differing doses and severity of the disease). </p> <section id="CD015391-sec-0069"> <h4 class="title">Primary outcomes</h4> <section id="CD015391-sec-0070"> <h5 class="title">All‐cause mortality at day 28</h5> <p>Both studies reported on all‐cause mortality either at day 15 (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>) or day 28 (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). Fluvoxamine may slightly reduce all‐cause mortality (RR 0.69, 95% CI 0.38 to 1.27; 1649 participants; RD 9 per 1000; <a href="./references#CD015391-fig-0002" title="">Analysis 1.1</a>). While no deaths were recorded in either the treatment group or placebo group at day 15 (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>), at day 28 the risk with fluvoxamine and standard care was 21 per 1000 and the risk in the placebo group was 30 per 1000 (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). Certainty of the evidence for this outcome was low. While we did not downgrade for risk of bias (as the study with a high risk of bias had a weight of 0% (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>), we did downgrade for very serious imprecision because the 95% CI suggests both potential benefit and no effect or potential harm, and the number of events was small. </p> </section> <section id="CD015391-sec-0071"> <h5 class="title">All‐cause admission to a hospital or death (before hospital admission)</h5> <p>Both studies reported data on admission to hospital or death within 28 days for participants with symptomatic COVID‐19. Fluvoxamine may reduce admission to hospital or death (RR 0.55, 95% CI 0.16 to 1.89; 1649 participants; RD 57 per 1000; <a href="./references#CD015391-fig-0003" title="">Analysis 1.2</a>). Certainty of the evidence for this outcome was low. We downgraded this by two levels due to concerns of very serious imprecision because the 95% CI suggests both potential benefit and no effect or potential harm, and the number of events was small. </p> </section> <section id="CD015391-sec-0072"> <h5 class="title">Symptom resolution</h5> <p>Neither of the studies reported numerical data for this outcome. One study illustrated data in a graph that indicated an overlap of confidence intervals (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). </p> </section> <section id="CD015391-sec-0073"> <h5 class="title">Quality of life</h5> <p>Neither of the studies reported this outcome.</p> </section> <section id="CD015391-sec-0074"> <h5 class="title">Serious adverse events</h5> <p>Both studies reported data for this outcome (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). There is very low‐certainty evidence on fluvoxamine regarding the number of participants with serious adverse events during the study period (RR 0.56, 95% CI 0.15 to 2.03; 1649 participants; RD 54 per 1000; <a href="./references#CD015391-fig-0004" title="">Analysis 1.3</a>). We downgraded the certainty of the evidence by three levels: by one level for serious concerns due to high risk of bias (measurement of the outcome), and by two levels for very serious concerns due to imprecision. The 95% CI includes a potential benefit and harm. </p> </section> <section id="CD015391-sec-0075"> <h5 class="title">Any adverse events (any grade)</h5> <p>The studies of <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> and <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> also reported data for any adverse events. There is very low‐certainty evidence on fluvoxamine regarding adverse events of any grade during the short‐term follow‐up (RR 1.06, 95% CI 0.82 to 1.37; 1649 participants; RD 7 per 1000; <a href="./references#CD015391-fig-0005" title="">Analysis 1.4</a>). We downgraded the certainty of the evidence by three levels: by one level for serious concerns due to high risk of bias (measurement of the outcome), and by two levels for very serious concerns due to imprecision. The 95% CI includes a potential benefit and harm. </p> </section> <section id="CD015391-sec-0076"> <h5 class="title">Suicide or suicide attempt</h5> <p>None of the included studies reported this outcome.</p> </section> </section> <section id="CD015391-sec-0077"> <h4 class="title">Secondary outcomes</h4> <p>The secondary outcomes reported included 'clinical status' at day 15, 28 or the longest follow‐up and 'viral clearance'. Clinical status was measured in one study each as 'need for invasive mechanical ventilation', 'need for non‐invasive mechanical ventilation or high flow' and 'need for hospitalisation with oxygen therapy'. Quantitative data for the secondary outcomes are listed in <a href="#CD015391-tbl-0003">Table 2</a>. </p> <div class="table" id="CD015391-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect estimate (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fluvoxamine</b> </p> <p><b>n/N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> <p><b>n/N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measures of heterogeneity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for invasive mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.77</p> <p>(0.45 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1497<sup>a</sup>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/741</p> <p>(3,5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/756</p> <p>(4,5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> </p> <p>no significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for non‐invasive mechanical ventilation or high flow (ventilator support)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD: 0.00</p> <p>(‐8.41 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/80</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/72</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> </p> <p>no significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for hospitalisation (with oxygen therapy by masks or nasal prongs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD: ‐4.21</p> <p>(‐13.22 to 2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/80</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/72</p> <p>(4.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> </p> <p>no significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral clearance (assessed with RT‐PCR) at day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR: 0.67</p> <p>(0.42 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428<sup>b</sup> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/207</p> <p>(19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58/221</p> <p>(26%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> </p> <p>no significant difference</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AD: absolute difference; n: number of events; N: number of participants; NA: not applicable; OR: odds ratio; RR: relative risk; RT‐PCR: reverse transcription‐polymerase chain reaction </p> <p><sup>a</sup> Number of participants hospitalised.<br/><sup>b</sup> Number of participants available for outcome assessment. </p> </div> </div> <section id="CD015391-sec-0078"> <h5 class="title">Need for invasive mechanical ventilation</h5> <p><a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> reported that 26 of 741 fluvoxamine treated patients versus 34 of 756 participants in the placebo group needed mechanical ventilation (RR 0.77, 95% CI 0.45 to 1.30; 1497 participants; RD 10 per 1000; <a href="#CD015391-tbl-0003">Table 2</a>). </p> </section> <section id="CD015391-sec-0079"> <h5 class="title">Need for non‐invasive mechanical ventilation or high flow</h5> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> reported that none of the 80 fluvoxamine treated participants versus three of 72 participants in the placebo group required supplemental oxygen plus ventilator support for three days or more (absolute difference 0.00, 95% CI ‐8.41 to 0.49; 152 participants; RD 0 per 1000; <a href="#CD015391-tbl-0003">Table 2</a>). This outcome was assessed with a 7‐point scale. </p> </section> <section id="CD015391-sec-0080"> <h5 class="title">Need for hospitalisation with oxygen therapy by masks or nasal prongs</h5> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> also reported that none of the 80 participants treated with fluvoxamine versus three of 72 participants in the placebo group needed hospitalisation and required supplemental oxygen therapy by masks or nasal prongs (absolute difference ‐4.21, 95% CI ‐13.22 to 2.04; 152 participants; RD 42 per 1000; <a href="#CD015391-tbl-0003">Table 2</a>). Again, this outcome was assessed with a 7‐point scale. </p> </section> <section id="CD015391-sec-0081"> <h5 class="title">Viral clearance (assessed with PCR) at day 7</h5> <p><a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> reported that 40 of 207 fluvoxamine treated patients versus 58 of 221 participants in the placebo group showed successful viral clearance at day seven (OR 0.67, 95% CI 0.42 to 1.06; 428 participants; RD 70 per 1000; <a href="#CD015391-tbl-0003">Table 2</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015391-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015391-sec-0082"></div> <section id="CD015391-sec-0083"> <h3 class="title" id="CD015391-sec-0083">Summary of main results</h3> <p>The aim of this review was to investigate the efficacy and safety of fluvoxamine in people with COVID‐19. We identified two RCTs including more than 1500 non‐hospitalised people (outpatients) with symptomatic COVID‐19 (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). We did not find any RCTs that investigated asymptomatic people or those hospitalised with COVID‐19 who were being treated with fluvoxamine. </p> <p>Both included studies evaluated composite endpoints including clinical worsening according to the definition of the respective study and retention in a COVID‐19 emergency setting or inpatient setting. From the prioritised primary endpoints of this review, the studies reported all‐cause mortality at day 28 (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>), admission to hospital (all cause) or death (before hospital admission) (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>), serious adverse events (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>) and adverse events (any grade) (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). Furthermore, the studies also reported data for the secondary outcomes: need for mechanical ventilation (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>), need for non‐invasive mechanical ventilation or high flow oxygen supplementation (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>), need for hospitalisation with need for oxygen therapy (by masks or nasal prongs) (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>), and viral clearance at day 7 (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). </p> <p>Our analyses show that fluvoxamine compared to placebo (both in addition to standard care) may slightly reduce all‐cause mortality at day 28 (RR 0.69, 95% CI 0.38 to 1.27; 2 studies, 1649 participants; low‐certainty evidence) and may reduce the number of people admitted to a hospital or who died beforehand (RR 0.55, 95% CI 0.16 to 1.89; 2 studies, 57 participants; low‐certainty evidence). The number of serious adverse events did not clearly differ between fluvoxamine and placebo, and we are very uncertain about the effect of fluvoxamine on serious adverse events during the study period (RR 0.56, 95% CI 0.15 to 2.03; 2 studies, 1649 participants; very low‐certainty evidence). Likewise, we are very uncertain about the effect of fluvoxamine on adverse events of any grade (RR 1.06, 95% CI 0.82 to 1.37; 2 studies, 1649 participants; very low‐certainty evidence). Although <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> mentioned that there was no difference in time to symptom resolution between the groups, we could not derive any numerical data from this study and contacting the authors was unsuccessful. Neither study reported on quality of life or suicide and suicide attempt. </p> </section> <section id="CD015391-sec-0084"> <h3 class="title" id="CD015391-sec-0084">Overall completeness and applicability of evidence</h3> <p>The evidence summarised in this review applies to the use of fluvoxamine in symptomatic COVID‐19 outpatients. It is mainly restricted to unvaccinated people at high‐risk and the virus variants of concern that were present at the time of the conducted trials (up to August 2021). We did not identify any randomised trials for inpatients with moderate, severe and critical COVID‐19, or any studies reporting on fluvoxamine versus other active pharmacological comparators with proven effectiveness. </p> <p>One small study was conducted in a single geographical area of the USA, with recruitment between April and August 2020 (the first phase of the pandemic) (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>). The other, much larger, study was conducted in high‐risk people in Brazil and recruitment took place between January and August 2021 (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). The recruitment period in <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> was before the start of the vaccination campaign, and in <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> only 6% of recruited participants reported one dose of a COVID‐19 vaccine at the end of the trial. Taking into account that widespread vaccination programmes have now become established in some areas, it is very unclear whether the results of the studies can be transferred to a predominantly immunised population in case of a breakthrough infection. </p> <p>Particularly for immunocompromised people, who have a relevant risk of an inadequate immune response to vaccination, an effective treatment reducing disease progression would be clinically important. However, immunosuppression was an exclusion criterion in <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>, and in <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> the number of immunosuppressed participants was unclear. Older people were also underrepresented in both studies: the median age of participants was 46 years (intervention arm) and 45 years (control arm) in <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>, and 50% of participants in the <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> trial were younger than 50 years old. Because the focus of the study of <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> was people at high‐risk, the applicability of our findings for subgroups including the immunocompromised or older people must be applied with caution. </p> <p>Since recruitment in <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> was based on the results of rapid SARS‐CoV‐2 antigen testing, diagnostic uncertainty may be another limitation in the interpretation of the results of this study. However, the concordance of positive COVID‐19 rapid antigen tests with RT‐PCR was evaluated in a group of participants who underwent PCR testing. A concordance rate of greater than 99% for both tests collected at baseline was found. </p> <p>Furthermore, the changing dynamics in the development of virus variants, with possible limitations on the effectiveness of antiviral therapies, needs to be considered when interpreting these results. There are no studies to date that evaluate the efficacy of fluvoxamine in the presence of virus variants of concern. Furthermore, we currently we do not know how immunomodulators will be affected by viral variants. </p> </section> <section id="CD015391-sec-0085"> <h3 class="title" id="CD015391-sec-0085">Certainty of the evidence</h3> <p>We assessed the certainty of evidence for primary outcomes presented in the <a href="./full#CD015391-tbl-0001">summary of findings Table 1</a> according to <a href="./references#CD015391-bbs2-0075" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Schünemann 2020</a>, and this ranged from low to very low. We found all‐cause mortality and admission to hospital, or death prior to hospital admission, to have low‐certainty evidence. The certainty of evidence for the outcomes ‘serious adverse events’ and ‘adverse events of any grade’ was very low. Downgrading was due to very serious imprecision (because the 95% CI suggests both potential benefit and no effect or potential harm) and a serious risk of bias (because of concerns in measurement of the outcome 'adverse events' which were self‐reported in both studies). Although our findings are mainly restricted to unvaccinated persons and virus variants of concern that were present up to August 2021, we did not downgrade due to indirectness. The reason for not downgrading was due to the ongoing and still dynamic pandemic. Judging the effectiveness of current anti‐COVID‐19 therapies against emerging variants poses an enormous challenge, as has been seen with the assessment of vaccine effectiveness over the last year (<a href="./references#CD015391-bbs2-0023" title="AltmannDM , BoytonRJ , BealeR . Immunity to SARS-CoV-2 variants of concern. Science2021;371(6534):1103-4. [DOI: 10.1126/science.abg7404]">Altmann 2021</a>). </p> <p>In the current phase of the pandemic, it is also impossible to reliably assess the risk of publication bias. There are registered studies that are ongoing. We will follow the publication and trial history of each ongoing study, including those awaiting classification. We do not suspect any current publication bias to be present, for any of the outcomes. However, this may change in future updates of this review. </p> </section> <section id="CD015391-sec-0086"> <h3 class="title" id="CD015391-sec-0086">Potential biases in the review process</h3> <p>To avoid potential bias in the review process, we committed ourselves to conducting this systematic review according to published guidance provided by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015391-bbs2-0040" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2020b</a>). </p> <p>Furthermore, this review is part of a Cochrane Living Systematic Reviews Series on different interventions for treatment of COVID‐19 (<a href="./references#CD015391-bbs2-0024" title="AnsemsK , GrundeisF , DahmsK , MikolajewskaA , ThiemeV , PiechottaV , et al. Remdesivir for the treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014962. [DOI: 10.1002/14651858.CD014962]">Ansems 2021</a>; <a href="./references#CD015391-bbs2-0049" title="KreuzbergerN , HirschC , ChaiKL , TomlinsonE , KhosraviZ , PoppM , et al. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 9. Art. No: CD013825. [DOI: 10.1002/14651858.CD013825.pub2]">Kreuzberger 2021</a>; <a href="./references#CD015391-bbs2-0067" title="PoppM , StegemannM , RiemerM , Metzendorf M-I, RomeroCS , MikolajewskaA , et al. Antibiotics for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 10. Art. No: CD015025. [DOI: 10.1002/14651858.CD015025]">Popp 2021a</a>; <a href="./references#CD015391-bbs2-0068" title="PoppM , StegemannM , MetzendorfMI , GouldS , KrankeP , MeybohmP , et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub2]">Popp 2021b</a>; <a href="./references#CD015391-bbs2-0079" title="StroehleinJK , WallqvistJ , IannizziC , MikolajewskaA , MetzendorfMI , BenstoemC , et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD015043. [DOI: 10.1002/14651858.CD015043]">Stroehlein 2021</a>; <a href="./references#CD015391-bbs2-0085" title="WagnerC , GrieselM , MikolajewskaA , MuellerA , NothackerM , KleyK , et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014963. [DOI: 10.1002/14651858.CD014963]">Wagner 2021</a>). Initially, a common core outcome set was established for all reviews in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for people with COVID‐19 (<a href="./references#CD015391-bbs2-0028" title="COMET Initiative. Core outcome set developers’ response to COVID-19; April 2021. www.comet-initiative.org/Studies/Details/1538.">COMET 2021</a>; <a href="./references#CD015391-bbs2-0053" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]]">Marshall 2020</a>). These outcomes are continuously discussed and modified as necessary, taking into account the dynamics of the pandemic. </p> <p>Although we did not exclude preprint studies, this review contains data from peer‐reviewed journal publications only. We contacted study authors if the publication included unclear or missing information. Details of communication with authors are provided in <a href="#CD015391-tbl-0002">Table 1</a>. </p> <p>Two trials are classified as awaiting classification either due to inconclusive information regarding outcome measures related to the language of the study (trial in Persian language in an inpatient setting), or because the study was stopped for futility by a data safety monitoring board and results have not been published (trial in an inpatient setting). We will closely monitor these trials for further publications in the near future. </p> <p>None of the authors has an affiliation with a stakeholder group that favours or disapproves of any selective serotonin reuptake inhibitors, or any of the comparators used in relevant studies. </p> </section> <section id="CD015391-sec-0087"> <h3 class="title" id="CD015391-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>We have identified two published reviews dedicated solely to the efficacy and safety of fluvoxamine in the treatment of COVID‐19 (<a href="./references#CD015391-bbs2-0047" title="KacimiSE , GrecaE , HairecheMA , ElHawarySA , SettiMO , CaruanaR , et al. The place of fluvoxamine in the treatment of non-critically ill patients with COVID-19: a living systematic review and meta-analysis. medRxiv2021. [DOI: 10.1101/2021.12.19.21268044]">Kacimi 2021</a>; <a href="./references#CD015391-bbs2-0051" title="LeeTC , VigodS , Bortolussi-CourvalE , HanulaR , BoulwareDR , LenzeEJ , et al. Fluvoxamine for outpatient COVID-19 to prevent hospitalization: a systematic review and meta-analysis. medRxiv. [DOI: 10.1101/2021.12.17.21268008]">Lee 2021</a>). Only one review, published as a preprint, analysed randomised trials (<a href="./references#CD015391-bbs2-0051" title="LeeTC , VigodS , Bortolussi-CourvalE , HanulaR , BoulwareDR , LenzeEJ , et al. Fluvoxamine for outpatient COVID-19 to prevent hospitalization: a systematic review and meta-analysis. medRxiv. [DOI: 10.1101/2021.12.17.21268008]">Lee 2021</a>), while <a href="./references#CD015391-bbs2-0047" title="KacimiSE , GrecaE , HairecheMA , ElHawarySA , SettiMO , CaruanaR , et al. The place of fluvoxamine in the treatment of non-critically ill patients with COVID-19: a living systematic review and meta-analysis. medRxiv2021. [DOI: 10.1101/2021.12.19.21268044]">Kacimi 2021</a> also considered observational studies. </p> <p><a href="./references#CD015391-bbs2-0051" title="LeeTC , VigodS , Bortolussi-CourvalE , HanulaR , BoulwareDR , LenzeEJ , et al. Fluvoxamine for outpatient COVID-19 to prevent hospitalization: a systematic review and meta-analysis. medRxiv. [DOI: 10.1101/2021.12.17.21268008]">Lee 2021</a> came to similar conclusions as our review. However, that review included three randomised trials. Besides the study of <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> and <a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>, the review considered a third completed, but not published, trial (<a href="./references#CD015391-bbs2-0058" title="NCT04668950. Fluvoxamine for early treatment of Covid-19 (Stop Covid 2). clinicaltrials.gov/ct2/show/NCT04668950 (first received 16 December 2020).">NCT04668950</a>). The authors stated that they obtained outcome data directly from the principal investigators (who were co‐authors of the cited review). </p> <p><a href="./references#CD015391-bbs2-0047" title="KacimiSE , GrecaE , HairecheMA , ElHawarySA , SettiMO , CaruanaR , et al. The place of fluvoxamine in the treatment of non-critically ill patients with COVID-19: a living systematic review and meta-analysis. medRxiv2021. [DOI: 10.1101/2021.12.19.21268044]">Kacimi 2021</a> (a preprint labelled as a living systematic review) also focused on fluvoxamine and included two randomised trials and one observational study. The authors concluded that repurposing of fluvoxamine for the treatment of people with COVID‐19 had not shown any efficacy in reducing the mortality rate or the rate of progress to mechanical ventilation. Although the authors described a reduced risk of hospitalisation amongst people with COVID‐19, they stressed that there was still an urgent need for more clinical studies to determine the extent of the effectiveness of fluvoxamine, and to know more about its mechanism of action in people with COVID‐19. </p> <p>There are several reviews analysing fluvoxamine as one of the therapeutics for COVID‐19.</p> <p>A systematic review by <a href="./references#CD015391-bbs2-0055" title="MurchuOE , SpillaneS , ByrneP , O’NeillM , HarringtonP , RyanM . Interventions in an ambulatory setting to prevent progression to severe disease in patients with COVID-19: a systematic review. Annals of Pharmacotherapy2022;56(3):309-18. [DOI: 10.1177/10600280211028242]">Murchu 2022</a> focused on differing oral interventions (including fluvoxamine, bamlanivimab as monotherapy and combined with etesevimab, casirivimab plus imdevimab, ivermectin, nitazoxanide, and peginterferon lambda) in the outpatient setting to prevent progression to severe disease in people with COVID‐19. Although this review did not include the large TOGETHER trial on fluvoxamine (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>), and most findings of the evaluated medications were based on single study results, the authors concluded that promising results in relation to clinical deterioration (defined by dyspnoea or hospitalisation), oxygen saturation (on room air) or need for supplemental oxygen (in the ambulatory setting) are available. </p> <p><a href="./references#CD015391-bbs2-0087" title="WenW , ChenC , TangJ , WangC , ZhouM , ChengY , et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Annals of Medicine2022;54(1):516-23. [DOI: 10.1080/07853890.2022.2034936]">Wen 2022</a> conducted a meta‐analysis to investigate the effectiveness of fluvoxamine and other oral antivirals (molnupiravir and nirmatrelvir/ritonavir). The authors included both randomised and non‐randomised trials and concluded that each oral medication assessed was effective in reducing mortality and hospitalisation rates in people with COVID‐19. In addition, they found that the risk of adverse events did not increase whilst taking medication compared to placebo or standard care. Taking into account that no bias assessment had been conducted, and the study results were combined without differentiating between inpatient and outpatient settings, these findings needed to be interpreted with caution. </p> <p>Based on their review of trials, including two RCTs which had the greatest impact on the Panel's recommendation (<a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a>; <a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>), the U.S. National Institutes of Health COVID‐19 Treatment Guidelines Panel stated that there is insufficient evidence to recommend either for or against the use of fluvoxamine in the treatment of COVID‐19 (<a href="./references#CD015391-bbs2-0056" title="National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. www.covid19treatmentguidelines.nih.gov/ (accessed 17 February 2022).">National Institutes of Health 2022</a>). </p> <p>Although there are some published reviews on fluvoxamine as early treatment for COVID‐19, none fulfilled all the methodological standards for evidence syntheses, and they did not apply the GRADE approach for rating the certainty of the evidence. But, overall, the findings of these reviews are in alignment with our review, indicating that the current evidence for fluvoxamine is limited, especially considering that only two randomised controlled trials currently exist. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015391-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/urn:x-wiley:14651858:media:CD015391:CD015391-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Figure 1: PRISMA flow diagram of study selection" data-id="CD015391-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_t/tCD015391-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p><b>Figure 1: PRISMA flow diagram of study selection</b> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015391-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/urn:x-wiley:14651858:media:CD015391:CD015391-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19, Outcome 1: All‐cause mortality (at day 28)" data-id="CD015391-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_t/tCD015391-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19, Outcome 1: All‐cause mortality (at day 28) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015391/references#CD015391-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015391-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/urn:x-wiley:14651858:media:CD015391:CD015391-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19, Outcome 2: All‐cause hospital admission or death (before hospital admission)" data-id="CD015391-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_t/tCD015391-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19, Outcome 2: All‐cause hospital admission or death (before hospital admission) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015391/references#CD015391-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015391-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/urn:x-wiley:14651858:media:CD015391:CD015391-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19, Outcome 3: Serious adverse events" data-id="CD015391-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_t/tCD015391-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19, Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015391/references#CD015391-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015391-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/urn:x-wiley:14651858:media:CD015391:CD015391-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19, Outcome 4: Adverse events (any grade)" data-id="CD015391-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_t/tCD015391-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19, Outcome 4: Adverse events (any grade) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015391/references#CD015391-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015391/media/CDSR/CD015391/image_n/nCD015391-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015391-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> symptomatic people with COVID‐19 </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> fluvoxamine plus standard care </p> <p><b>Comparison:</b> placebo plus standard care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects (95% CI)*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>N of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty in the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo plus standard care</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with fluvoxamine plus standard care</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p>(at day 28)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> <p>(95% CI 11 to 38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> <p>(95% CI 2 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.69</p> <p>(0.38 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluvoxamine may slightly reduce all‐cause mortality at day 28.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>All‐cause admission to hospital or death (before hospital admission)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> <p>(95% CI 105 to 150)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> <p>(95% CI 76 to 116)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.55</p> <p>(0.16 to 1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649</p> <p>(2 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fluvoxamine may reduce admission to hospital or death (before hospital admission).</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Symptom resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>All initial symptoms resolved</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Time to symptom resolution</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Numerical data not derivable, outcome was illustrated in a figure (graph) indicating an overlap of confidence intervals (<a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Quality of life</b> </p> <p>(at longest follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during study period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000 (95% CI 18 to 248)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> <p>(95% CI 41 to 221)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.56</p> <p>(0.15 to 2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effects of fluvoxamine on serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Any adverse events</b> </p> <p>(during study period)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> <p>(95% CI 97 to 162)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> <p>(95% CI 104 to 169)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06</p> <p>(0.82 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1649</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The evidence is very uncertain about the effects of fluvoxamine on any adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Suicide or suicide attempt</b> </p> <p>(at longest follow‐up)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The risk in the intervention group and its 95% CI is based on the assumed risk in the comparison group and the relative effect of the intervention and its 95% CI. </p> <p>CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Risk difference 9 per 1000 (19 fewer to 8 more), small important effect (since mortality is the most critical outcomes for patients and clinicians). Downgraded by 2 levels for very serious imprecision since CI suggests both potential benefit and no effect/potential harm, and number of events is small.<br/><sup>b</sup>Risk difference 57 per 1000 (106 fewer to 112 more), moderate effect. Downgraded by 2 levels for very serious imprecision since CI suggests both potential benefit and no effect/potential harm, and number of events is small.<br/><sup>c</sup>Risk difference 54 per 1000 (50 fewer to 4 more), moderate effect. Downgraded by 1 level for serious risk of bias and by 2 levels for very serious imprecision since CI suggests both potential benefit and potential harm.<br/><sup>d</sup>Risk difference 7 per 1000 (21 fewer to 44 more), small unimportant effect. Downgraded by 1 level for serious risk of bias and by 2 levels for very serious imprecision since CI suggests both potential benefit and potential harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015391-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Author communication</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Date of request and question of the authors' of this review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Date when feedback was received and author response provided</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 June 2022: Question regarding the outcome 'all‐cause hospitalisation', which is mentioned in the primary study, but definite numerical data were missing. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 June 2022: Numbers for all‐cause hospitalisation: 1 participant in the fluvoxamine and 5 participants in the placebo group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 January 2022: Question regarding the outcome 'symptom resolution' which is mentioned in the primary study, but definite numerical data are not reported. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Feedback was not provided.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Communications are listed after considering communication date</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Author communication</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015391-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Effect estimate (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>N of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fluvoxamine</b> </p> <p><b>n/N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> <p><b>n/N</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Measures of heterogeneity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for invasive mechanical ventilation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.77</p> <p>(0.45 to 1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1497<sup>a</sup>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/741</p> <p>(3,5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/756</p> <p>(4,5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> </p> <p>no significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for non‐invasive mechanical ventilation or high flow (ventilator support)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD: 0.00</p> <p>(‐8.41 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/80</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/72</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> </p> <p>no significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Need for hospitalisation (with oxygen therapy by masks or nasal prongs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD: ‐4.21</p> <p>(‐13.22 to 2.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/80</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/72</p> <p>(4.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0001" title="LenzeEJ , MattarC , ZorumskiCF , StevensA , SchweigerJ , NicolGE , et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. Journal of the American Medical Association2020;324(22):2292-2300. NCT04342663. A double-blind, placebo-controlled clinical trial of fluvoxamine for symptomatic individuals with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04342663 (first received 13 April 2020). ">Lenze 2020</a> </p> <p>no significant difference</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Viral clearance (assessed with RT‐PCR) at day 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR: 0.67</p> <p>(0.42 to 1.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>428<sup>b</sup> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/207</p> <p>(19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58/221</p> <p>(26%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD015391-bbs2-0002" title="NCT04727424. Repurposed approved and under development therapies for patients with early-onset COVID-19 and mild symptoms. www.clinicaltrials.gov/ct2/show/NCT04727424 (first received 27 January 2021). ReisG , Dos Santos Moreira-SilvaEA , SilvaDC , ThabaneL , MilagresAC , FerreiraTS , et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Global Health2021;10(1):e42-e51. [DOI: 10.1016/S2214-109X(21)00448-4]">TOGETHER 2021</a> </p> <p>no significant difference</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AD: absolute difference; n: number of events; N: number of participants; NA: not applicable; OR: odds ratio; RR: relative risk; RT‐PCR: reverse transcription‐polymerase chain reaction </p> <p><sup>a</sup> Number of participants hospitalised.<br/><sup>b</sup> Number of participants available for outcome assessment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015391/full#CD015391-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015391-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality (at day 28) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.38, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause hospital admission or death (before hospital admission) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.16, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.15, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse events (any grade) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.82, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluvoxamine plus standard care compared to placebo plus standard care for outpatients with mild COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015391/references#CD015391-tbl-0004">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality (at day 28)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lenze 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients were randomized 1:1 to fluvoxamine or matching placebo capsules. Randomization schedules were generated that stratified by age (18‐44, 45‐54, 55‐64, and ≥65 years)16 and sex. Treatments were randomly allocated using alternating block sizes of 2 and 4. Randomization allocation was conducted via REDCap, which displayed randomization assignment to the laboratory manager (J.S.), who prepared the study materials, including the study drug or placebo. All outcome assessors, investigators, and research staff who were in contact with participants were blinded to participant treatment assignment." "Participants were well‐matched in demographic and clinical characteristics. The baseline oxygen saturation level did not differ between the groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Placebo controlled trial. All outcome assessors, investigators, and research staff who were in<br/>contact with participants were blinded to participant treatment assignment. </p> <p>There is a substantial number of participants who did not complete the study. There were 18 out of 80 (22.5%) in intervention group and 19 out of 72 (26.4%) in the placebo group. Patients were analysed according to randomization group. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>37 study participants did not finish the study. 18 patients in the intervention group and 19 patients in the placebo group did not complete the study. <br/>No evidence to support that the results were not bias by missing outcome data. <br/>The missing patients might have different outcomes compared to the patients that remained in the trial. <br/>High proportion of withdrawals without explanation </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No detailed information on outcome measurement reported. Medical records were used to measure outcomes that were not self‐reported. No patients died during the trial. <br/>Participants and personnel were blinded to the treatment, so differences in the ascertainment of the outcome are unlikely. Ascertainment of mortality considered objective enough. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The primary analysis reported agrees with that of the protocol. <br/>Unlikely that multiple outcome measures or analyses were used since 0 patients died during the trial. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients were randomized 1:1 to fluvoxamine or matching<br/>placebo capsules. Randomization schedules were generated<br/>that stratified by age (18‐44, 45‐54, 55‐64, and ≥65 years)16<br/>and sex. Treatments were randomly allocated using alternating<br/>block sizes of 2 and 4. Randomization allocation was conducted<br/>via REDCap, which displayed randomization assignment<br/>to the laboratory manager (J.S.), who prepared the<br/>study materials, including the study drug or placebo. All outcome<br/>assessors, investigators, and research staff who were in<br/>contact with participants were blinded to participant treatment<br/>assignment." </p> <p>"Participants were well‐matched in demographic and clinical characteristics. The baseline oxygen saturation level did not differ between the groups."<br/>No, placebo controlled trial. All outcome assessors, investigators, and research staff who were in<br/>contact with participants were blinded to participant treatment<br/>assignment. </p> <p>There is a substantial number of participants who did not complete the study. There were 18 in intervention group and 19 in the placebo group. <br/>Patients were analysed according to randomization group. </p> <p>37 study participants did not finish the study. 18 patients in the intervention group and 19 patients in the placebo group did not complete the study. <br/>No evidence to support that the results were not bias by missing outcome data. <br/>The missing patients might have different outcomes compared to the patients that remained in the trial. <br/>High proportion of the withdrawals had no reason explaining it. <br/>No detailed information on outcome measurement reported. Medical records were used to measure outcomes that were not self‐reported. No patients died during the trial. <br/>Participants and personnel were blinded to the treatment, so differences in the ascertainment of the outcome are unlikely. Ascertainment of mortality considered subjective enough. <br/>Participants and personnel were blinded to the treatment, so differences in the ascertainment of the outcome are unlikely. </p> <p>The primary analysis reported in the paper agrees with that of the protocol. <br/>Unlikely that multiple outcome measures or analyses were used since 0 patients died during the trial. </p> </td> </tr> <tr class="study-data"> <td> <p>TOGETHER 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Participants were randomly assigned by means of a centralised core randomisation process handled by an independent unmasked pharmacist who was not aware of any protocol‐related procedures and contracted specifically for this process. Patients were randomly assigned (1:1) by means of a block randomisation procedure for each participating site, stratified by age (&lt;50 years or ≥50 years)."<br/>Quote: "With respect to covariates of age,<br/>body‐mass index, and comorbidities, the groups were generally well balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial team, site staff, and patients were masked to treatment allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and labelled with alphabet letters corresponding to the active group or placebo group." </p> <p>Comment: Patients were analysed according to randomization group with intention‐to treat analyses. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "84 participants stopped fluvoxamine and 64 participants stopped placebo owing to issues of tolerability." <br/>Comment: Proportions of drop‐out are comparable between groups and &lt; 12%. This proportion seems tolerable and is not considered to introduce bias to the results. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Study personnel collected outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28 in person or via telephone contact or social media applications using video‐teleconferencing. We collected outcome data irrespective of whether<br/>participants took study medication."<br/>Comment: All outcomes were reported to be self‐reported. No information about measuring mortality are reported. Outcome measurement or ascertainment of the outcome are unlikely to differ between groups for mortality. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Comment: The primary analysis reported in the paper agrees with that of the protocol. <br/>Numerical results are unlikely to be selected from multiple outcome measures or analyses. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Participants were randomly assigned by means of a centralised core randomisation process handled by an independent unmasked pharmacist who was not aware of any protocol‐related procedures and contracted specifically for this process. Patients were randomly assigned (1:1) by means of a block randomisation procedure for each participating site, stratified by age (&lt;50 years or ≥50 years)."<br/>Quote: "With respect to covariates of age,<br/>body‐mass index, and comorbidities, the groups were generally well balanced." </p> <p>Quote: "The trial team, site staff, and patients were masked to treatment allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and labelled with alphabet letters corresponding to the active group or placebo group." </p> <p>Comment: Patients were analysed according to randomization group with intention‐to treat analyses. </p> <p>Quote: "84 participants stopped fluvoxamine and 64 participants<br/>stopped placebo owing to issues of tolerability." <br/>Comment: Proportions of drop‐out are comparable between groups and &lt; 12%. This proportion seems tolerable and is not considered to introduce bias to the results. </p> <p>Quote: "Study personnel collected outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28 in person or via telephone contact or social media applications using video‐teleconferencing.<br/>We collected outcome data irrespective of whether<br/>participants took study medication."<br/>Comment: All outcomes were reported to be self‐reported. No information about measuring mortality are reported. <br/>Comment: Outcome measurement or ascertainment of the outcome are unlikely to differ for mortality. </p> <p>Comment: The primary analysis reported in the paper agrees with that of the protocol. <br/>Comment: Numerical results are unlikely to be selected from multiple outcome measures or analyses. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality (at day 28)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015391/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 All‐cause hospital admission or death (before hospital admission)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lenze 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients were randomized 1:1 to fluvoxamine or matching placebo capsules. Randomization schedules were generated that stratified by age (18‐44, 45‐54, 55‐64, and ≥65 years)16 and sex. Treatments were randomly allocated using alternating block sizes of 2 and 4. Randomization allocation was conducted via REDCap, which displayed randomization assignment to the laboratory manager (J.S.), who prepared the study materials, including the study drug or placebo. All outcome assessors, investigators, and research staff who were in contact with participants were blinded to participant treatment assignment." "Participants were well‐matched in demographic and clinical characteristics. The baseline oxygen saturation level did not differ between the groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>All outcome assessors, investigators, and research staff who were in contact with participants were blinded to participant treatment assignment. Patients were analyzed according to randomization group. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Although 37 study participants did not finish the study. 18 patients in the intervention group and 19 patients in the placebo group did not complete the study, the authors performed a senstivity analysis to assess the missing data. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>In this case we consider hospitalisation as obejctive enough to allow for an unbiased assessment. Study personnel and participants were blinded to the intervention. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The primary analysis reported in the paper agrees with that of the protocol. Unlikely that multiple outcome measures or analyses were used since 0 patients died during the trial. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr class="study-data"> <td> <p>TOGETHER 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Participants were randomly assigned by means of a centralised core randomisation process handled by an independent unmasked pharmacist who was not aware of any protocol‐related procedures and contracted specifically for this process. Patients were randomly assigned (1:1) by means of a block randomisation procedure for each participating site, stratified by age (&lt;50 years or ≥50 years)."<br/>Quote: "With respect to covariates of age,<br/>body‐mass index, and comorbidities, the groups were generally well balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial team, site staff, and patients were masked to treatment allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and labelled with alphabet letters corresponding to the active group or placebo group." </p> <p>Comment: Patients were analysed according to randomization group with intention‐to treat analyses. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "84 participants stopped fluvoxamine and 64 participants stopped placebo owing to issues of tolerability." <br/>Comment: Proportions of drop‐out are comparable between groups and &lt; 12%. This proportion seems tolerable and is not considered to introduce bias to the results. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Study personnel collected outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28 in person or via telephone contact or<br/>social media applications using video‐teleconferencing. We collected outcome data irrespective of whether<br/>participants took study medication."<br/>Comment: All outcomes were reported to be self‐reported. Hospital admission is judged to be objective enough to allow for an unbiased assessment. Outcome measurement or ascertainment of the outcome are unlikely to differ between both groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Comment: The primary analysis reported in the publication agrees with that of the protocol. </p> <p>Numerical results are unlikely to be selected from multiple outcome measures or analyses. Outcomes are sufficiently different and details are reported for each measurement separately. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Participants were randomly assigned by means of a centralised core randomisation process handled by an independent unmasked pharmacist who was not aware of any protocol‐related procedures and contracted specifically for this process. Patients were randomly assigned (1:1) by means of a block randomisation procedure for each participating site, stratified by age (&lt;50 years or ≥50 years)."<br/>Quote: "With respect to covariates of age,<br/>body‐mass index, and comorbidities, the groups were generally well balanced." </p> <p>Quote: "The trial team, site staff, and patients were masked to treatment allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and labelled with alphabet letters corresponding to the active group or placebo group." </p> <p>Comment: Patients were analysed according to randomisation group with intention‐to treat analyses. <br/>Quote: "We assessed time‐to‐event outcomes<br/>using<br/>Cox proportional hazard models and binary outcomes<br/>using logistic regression." </p> <p>Quote: "84 participants stopped fluvoxamine and 64 participants<br/>stopped placebo owing to issues of tolerability." <br/>Comment: Proportions of drop‐out are comparable between groups and &lt; 12%. This proportion seems tolerable and is not considered to introduce bias to the results. </p> <p>Quote: "Study personnel collected outcome data on days 1, 2, 3,<br/>4, 5, 7, 10, 14, and 28 in person or via telephone contact or<br/>social media applications using video‐teleconferencing.<br/>We collected outcome data irrespective of whether<br/>participants took study medication."<br/>Comment: All outcomes were reported to be self‐reported. Hospital admission is judged to be objective enough to allow for an unbiased assessment. <br/>Comment: Outcome measurement or ascertainment of the outcome are unlikely to differ between both groups. </p> <p>Comment: The primary analysis reported in the paper agrees with that of the protocol. <br/>Comment: Numerical results are unlikely to be selected from multiple outcome measures or analyses. Outcomes re sufficiently different and details are reported for each measurement separately. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 All‐cause hospital admission or death (before hospital admission)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015391/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lenze 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients were randomized 1:1 to fluvoxamine or matching placebo capsules. Randomization schedules were generated that stratified by age (18‐44, 45‐54, 55‐64, and ≥65 years)16 and sex. Treatments were randomly allocated using alternating block sizes of 2 and 4. Randomization allocation was conducted via REDCap, which displayed randomization assignment to the laboratory manager (J.S.), who prepared the study materials, including the study drug or placebo. All outcome assessors, investigators, and research staff who were in contact with participants were blinded to participant treatment assignment." "Participants were well‐matched in demographic and clinical characteristics. The baseline oxygen saturation level did not differ between the groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Placebo controlled trial. All outcome assessors, investigators, and research staff who were in contact with participants were blinded to participant treatment assignment. </p> <p>There is a substantial number of participants who did not complete the study. There were 18 out of 80 (22.5%) in the intervention group and 19 out of 72 (26.4%) in the placebo group. <br/>Quote: "the data appeared to be missing at random and no data imputation was conducted" </p> <p>Comment: For missing data, the researchers compared available scores with missing scores to check if the missing scores were non‐random. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>37 study participants did not complete the study. 18 patients in the intervention group and 19 patients in the placebo group did not complete the study. <br/>No evidence to support that the results were not bias by missing outcome data. </p> <p>Outcome data could potentially be missing when participants experienced serious adverse events. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Adverse events and serious adverse events were recorded each day via participant self‐report for 15 days after randomization." <br/>Comment: This was a remote trial with minimal patient‐practitioner contact. (Serious) adverse events were self‐reported and not verified by practitioner or medical record. Differences in measurement and ascertainment of the outcome unlikely between groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol states: "we will assess for adverse events (including serious adverse events) daily via participant self‐report during the first 15 days, and then again at the end of the study." </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients were randomized 1:1 to fluvoxamine or matching placebo capsules. Randomization schedules were generated<br/>that stratified by age (18‐44, 45‐54, 55‐64, and ≥65 years)16 and sex. Treatments were randomly allocated using alternating block sizes of 2 and 4. Randomization allocation was conducted<br/>via REDCap, which displayed randomization assignment to the laboratory manager (J.S.), who prepared the study materials, including the study drug or placebo. All outcome assessors, investigators, and research staff who were in<br/>contact with participants were blinded to participant treatment assignment." </p> <p>"Participants were well matched in demographic and clinical characteristics. The baseline oxygen saturation level did not differ between the groups."<br/>No, placebo controlled trial. All outcome assessors, investigators, and research staff who were in<br/>contact with participants were blinded to participant treatment assignment. </p> <p>There is a substantial number of participants who did not complete the study. There were 18 in intervention group and 19 in the placebo group. <br/>Quote: "the data appeared to be missing at random and no data imputation was conducted" </p> <p>Comment: For missing data, the researchers compared available scores with missing scores to check if the missing scores were non‐random. </p> <p>37 study participants did not finish the study. 18 patients in the intervention group and 19 patients in the placebo group did not complete the study. <br/>No evidence to support that the results were not bias by missing outcome data. <br/>Outcome data could potentially be missing when participants experienced serious adverse events. </p> <p>The outcomes for the missing observations would have been significantly different from the final participants analysed.<br/>Quote: Adverse events and serious adverse events were recorded each day via participant self‐report for 15 days after randomization. <br/>Comment: This was a remote trial with minimal patient‐practitioner contact. (Serious) adverse events were self‐reported and not verified by practitioner or medical record. <br/>Comment: Differences in measurement and ascertainment of the outcome unlikely. </p> <p>The protocol states: "we will assess for adverse events (including serious adverse events) daily via participant self‐report during the first 15 days, and then again at the end of the study." </p> </td> </tr> <tr class="study-data"> <td> <p>TOGETHER 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Participants were randomly assigned by means of a centralised core randomisation process handled by an independent unmasked pharmacist who was not aware of any protocol‐related procedures and contracted specifically for this process. Patients were randomly assigned (1:1) by means of a block randomisation procedure for each participating site, stratified by age (&lt;50 years or ≥50 years)."<br/>Quote: "With respect to covariates of age,<br/>body‐mass index, and comorbidities, the groups were generally well balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "The trial team, site staff, and patients were masked to treatment allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and labelled with alphabet letters corresponding to the active group or placebo group." </p> <p>Comment: Patients were analysed according to randomization group with intention‐to treat analyses. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "84 participants stopped fluvoxamine and 64 participants stopped placebo owing to issues of tolerability." <br/>Comment: Proportions of drop‐out are comparable between groups and &lt; 12%. This proportion seems tolerable and is not considered to introduce bias to the results. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Study personnel collected outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28 in person or via telephone contact or social media applications using video‐teleconferencing. We collected outcome data irrespective of whether participants took study medication."; "All serious and non‐serious adverse events were reported to study personnel as per local regulatory<br/>requirements."<br/>Comment: The outcomes appears to also be self‐reported. Outcome measurement or ascertainment of the outcome are unlikely to differ in both groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Comment: The primary analysis reported in the paper agrees with that of the protocol.</p> <p>Numerical results are unlikely to be selected from multiple outcome measures or analyses.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Participants were randomly assigned by means of a centralised core randomisation process handled by an independent unmasked pharmacist who was not aware of any protocol‐related procedures and contracted specifically for this process. Patients were randomly assigned (1:1) by means of a block randomisation procedure for each participating site, stratified by age (&lt;50 years or ≥50 years)."<br/>Quote: "With respect to covariates of age,<br/>body‐mass index, and comorbidities, the groups were generally well balanced." </p> <p>Quote: "The trial team, site staff, and patients were masked to treatment allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and labelled with alphabet letters corresponding to the active group or placebo group." </p> <p>Comment: Patients were analysed according to randomization group with intention‐to treat analyses. <br/>Quote: "84 participants stopped fluvoxamine and 64 participants stopped placebo owing to issues of tolerability." <br/>Comment: Proportions of drop‐out are comparable between groups and &lt; 12%. This proportion seems tolerable and is not considered to introduce bias to the results. </p> <p>Quote: "Study personnel collected outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28 in person or via telephone contact or social media applications using video‐teleconferencing.<br/>We collected outcome data irrespective of whether<br/>participants took study medication."<br/>Comment: All outcomes were reported to be self‐reported. <br/>Comment: Outcome measurement or ascertainment of the outcome are unlikely to differ in both groups. </p> <p>Comment: The primary analysis reported in the paper agrees with that of the protocol. <br/>Comment: Numerical results are unlikely to be selected from multiple outcome measures or analyses. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015391/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Adverse events (any grade)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Lenze 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col6" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients were randomized 1:1 to fluvoxamine or matching placebo capsules. Randomization schedules were generated that stratified by age (18‐44, 45‐54, 55‐64, and ≥65 years)16 and sex. Treatments were randomly allocated using alternating block sizes of 2 and 4. Randomization allocation was conducted via REDCap, which displayed randomization assignment to the laboratory manager (J.S.), who prepared the study materials, including the study drug or placebo. All outcome assessors, investigators, and research staff who were in contact with participants were blinded to participant treatment assignment." "Participants were well‐matched in demographic and clinical characteristics. The baseline oxygen saturation level did not differ between the groups." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Placebo controlled trial. All outcome assessors, investigators, and research staff who were in<br/>contact with participants were blinded to participant treatment assignment. </p> <p>Comment: For missing data, the researchers compared available scores with missing scores to check if the missing scores were non‐random. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>37 study participants did not finish the study. There were 18 out of 80 (22.5%) in the intervention group and 19 out of 72 (26.4%) in the placebo group. No evidence to support that the results were not bias by missing outcome data. The outcomes for the missing observations would have been significantly different from the final participants analysed. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Adverse events and serious adverse events were recorded each day via participant self‐report for 15 days after randomization." <br/>Comment: This was a remote trial with minimal patient‐practitioner contact. (Serious) adverse events were self‐reported and not verified by practitioner or medical record. Differences in measurement and ascertainment of outcome unlikely. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol states: "we will assess for adverse events (including serious adverse events) daily via participant self‐report during the first 15 days, and then again at the end of the study." </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Patients were randomized 1:1 to fluvoxamine or matching placebo capsules. Randomization schedules were generated<br/>that stratified by age (18‐44, 45‐54, 55‐64, and ≥65 years)16 and sex. Treatments were randomly allocated using alternating block sizes of 2 and 4. Randomization allocation was conducted<br/>via REDCap, which displayed randomization assignment to the laboratory manager (J.S.), who prepared the study materials, including the study drug or placebo. All outcome assessors, investigators, and research staff who were in<br/>contact with participants were blinded to participant treatment assignment." </p> <p>"Participants were well matched in demographic and clinical characteristics. The baseline oxygen saturation level did not differ between the groups."<br/>No, placebo controlled trial. All outcome assessors, investigators, and research staff who were in<br/>contact with participants were blinded to participant treatment<br/>assignment. </p> <p>There is a substantial number of participants who did not complete the study. There were 18 in intervention group and 19 in the placebo group. <br/>Quote: " the data appeared to be missing at random and no data imputation was conducted" </p> <p>37 study participants did not finish the study. 18 patients in the intervention group and 19 patients in the placebo group did not complete the study. <br/>No evidence to support that the results were not bias by missing outcome data. </p> <p>The outcomes for the missing observations would have been significantly different from the final participants analysed.<br/>Quote: Adverse events and serious adverse events were recorded each day via participant self‐report for 15 days after randomization. <br/>Comment: This was a remote trial with minimal patient‐practitioner contact. (Serious) adverse events were self‐reported and not verified by practitioner or medical record. <br/>Comment: Differences in measurement and ascertainment of outcome unlikely. </p> <p>In the protocol it states: "we will assess for adverse events (including serious adverse events) daily via participant self‐report during the first 15 days, and then again at the end of the study." </p> </td> </tr> <tr class="study-data"> <td> <p>TOGETHER 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col8" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Participants were randomly assigned by means of a centralised core randomisation process handled by an independent unmasked pharmacist who was not aware of any protocol‐related procedures and contracted specifically for this process. Patients were randomly assigned (1:1) by means of a block randomisation procedure for each participating site, stratified by age (&lt;50 years or ≥50 years)."<br/>Quote: "With respect to covariates of age,<br/>body‐mass index, and comorbidities, the groups were generally well balanced." </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No, The trial team, site staff, and patients were masked to treatment allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and labelled with alphabet letters corresponding to the active group or placebo group. </p> <p>Comment: Patients were analysed according to randomization group with intention‐to treat analysis. <br/>Quote: "We assessed time‐to‐event outcomes<br/>using Cox proportional hazard models and binary outcomes using logistic regression." </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "84 participants stopped fluvoxamine and 64 participants stopped placebo owing to issues of tolerability." <br/>Comment: Proportions of drop‐out are comparable between groups and &lt; 12%. This proportion seems tolerable and is not considered to introduce bias to the results. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Study personnel collected outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28 in person or via telephone contact or social media applications using video‐teleconferencing. We collected outcome data irrespective of whether<br/>participants took study medication."<br/>Comment: All outcomes were reported to be self‐reported. Outcome measurement or ascertainment of the outcome are unlikely to differ between both groups. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Comment: The primary analysis reported in the paper agrees with that of the protocol.</p> <p>Numerical results are unlikely to be selected from multiple outcome measures or analyses.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Quote: "Participants were randomly assigned by means of a centralised core randomisation process handled by an independent unmasked pharmacist who was not aware of any protocol‐related procedures and contracted specifically for this process. Sites requested randomisation by text message to the pharmacist at the coordinating centre.<br/>This maintained concealment of allocation. Patients were randomly assigned (1:1) by means of a block randomisation procedure for each participating site, stratified by age (&lt;50 years or ≥50 years)." </p> <p>"Participants were well matched in demographic and clinical characteristics."</p> <p>The trial team, site staff, and patients were masked to treatment allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and labelled with alphabet letters corresponding to the active group or placebo group. </p> <p>Comment: Patients were analysed according to randomization group with intention‐to treat analyses. <br/>Quote: "We assessed time‐to‐event outcomes<br/>using Cox proportional hazard models and binary outcomes using logistic regression." </p> <p>Quote: "84 participants stopped fluvoxamine and 64 participants stopped placebo owing to issues of tolerability." <br/>Comment: Proportions of drop‐out are comparable between groups and &lt; 12%. This proportion seems tolerable and is not considered to introduce bias to the results. </p> <p>Quote: "Study personnel collected outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28 in person or via telephone contact or social media applications using video‐teleconferencing.<br/>We collected outcome data irrespective of whether<br/>participants took study medication."<br/>Comment: All outcomes were reported to be self‐reported. </p> <p>Outcome measurement or ascertainment of the outcome are unlikely to differ both groups.</p> <p>The primary analysis reported in the paper agrees with that of the protocol.</p> <p>Numerical results are unlikely to be selected from multiple outcome measures or analyses.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Adverse events (any grade)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015391/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015391&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015391-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015391-note-0029">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015391-note-0024">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015391-note-0026">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD015391-note-0022">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD015391-note-0017">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD015391-note-0020">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD015391-note-0027">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD015391-note-0018">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD015391-note-0015">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015391-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015391-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015391\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015391"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015391\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015391\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015391"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015391\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015391"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015391\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015391\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015391"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015391&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015391';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015391/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015391/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015391%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716333904"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015391/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716333908"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015391/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9cf388079368',t:'MTc0MDcxNjMzNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 